

Giuseppe Remuzzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5360335/publications.pdf>

Version: 2024-02-01

1,362
papers

183,082
citations

68

173
h-index

53

392
g-index

1389
all docs

1389
docs citations

1389
times ranked

150608
citing authors

#	ARTICLE	IF	CITATIONS
1	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2095-2128.	13.7	11,038
2	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
3	Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2001, 345, 861-869.	27.0	6,609
4	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
5	Global, regional, and national ageâ€“sex specific all-cause and cause-specific mortality for 240 causes of death, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	13.7	5,847
6	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
7	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
8	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
9	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
10	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	13.7	2,858
11	COVID-19 and Italy: what next?. Lancet, The, 2020, 395, 1225-1228.	13.7	2,382
12	Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, The, 2003, 362, 1527-1535.	13.7	2,300
13	Organoid Models and Applications in Biomedical Research. Nephron, 2015, 130, 191-199.	1.8	2,247
14	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	13.7	2,184
15	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.	27.0	2,110
16	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 2009, 360, 1395-1407.	27.0	1,781
17	von Willebrand Factorâ€“Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 1998, 339, 1578-1584.	27.0	1,717
18	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612

#	ARTICLE	IF	CITATIONS
19	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	13.7	1,589
20	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
21	Terminal Complement Inhibitor Eculizumab in Atypical Hemolyticâ€Uremic Syndrome. New England Journal of Medicine, 2013, 368, 2169-2181.	27.0	1,258
22	Atypical Hemolyticâ€Uremic Syndrome. New England Journal of Medicine, 2009, 361, 1676-1687.	27.0	1,140
23	Pathophysiology of Progressive Nephropathies. New England Journal of Medicine, 1998, 339, 1448-1456.	27.0	1,137
24	The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney International, 2011, 80, 1258-1270.	5.2	1,105
25	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2129-2143.	13.7	1,013
26	Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2004, 351, 1941-1951.	27.0	952
27	Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Annals of Internal Medicine, 2001, 135, 73.	3.9	927
28	Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0147601.	2.5	882
29	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.	27.0	844
30	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International, 2004, 65, 2309-2320.	5.2	842
31	Delayed graft function in kidney transplantation. Lancet, The, 2004, 364, 1814-1827.	13.7	828
32	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1844-1859.	4.5	818
33	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, The, 1999, 354, 359-364.	13.7	800
34	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	13.7	786
35	International Society of Nephrology's Oby25 initiative for acute kidney injury (zero preventable deaths) Tj ETQq1 1 0,784314 rgBT /Over	13.7	780
36	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	13.7	740

#	ARTICLE	IF	CITATIONS
37	Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1794-1804.	6.1	690
38	Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. <i>Circulation</i> , 2004, 110, 921-927.	1.6	679
39	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet, The</i> , 2017, 390, 1888-1917.	13.7	662
40	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. <i>Blood</i> , 2006, 108, 1267-1279.	1.4	652
41	How Does Proteinuria Cause Progressive Renal Damage?. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2974-2984.	6.1	647
42	Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia. <i>New England Journal of Medicine</i> , 1983, 308, 8-12.	27.0	620
43	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. <i>Lancet, The</i> , 2010, 376, 1543-1551.	13.7	613
44	Overview of Complement Activation and Regulation. <i>Seminars in Nephrology</i> , 2013, 33, 479-492.	1.6	610
45	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. <i>Kidney International</i> , 2011, 79, 1331-1340.	5.2	609
46	Angiotensin II revisited: new roles in inflammation, immunology and aging. <i>EMBO Molecular Medicine</i> , 2010, 2, 247-257.	6.9	595
47	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. <i>Lancet, The</i> , 2005, 365, 939-946.	13.7	594
48	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	13.7	573
49	Understanding the nature of renal disease progression. <i>Kidney International</i> , 1997, 51, 2-15.	5.2	572
50	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	13.7	571
51	Chronic kidney disease. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17088.	30.5	558
52	Nephropathy in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2002, 346, 1145-1151.	27.0	537
53	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 884.	7.4	523
54	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. <i>Lancet, The</i> , 1998, 352, 1252-1256.	13.7	522

#	ARTICLE	IF	CITATIONS
55	Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. Journal of Clinical Investigation, 2006, 116, 288-296.	8.2	512
56	Thrombomodulin Mutations in Atypical Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 2009, 361, 345-357.	27.0	495
57	Progression, remission, regression of chronic renal diseases. Lancet, The, 2001, 357, 1601-1608.	13.7	491
58	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
59	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA Pediatrics, 2016, 170, 267.	6.2	479
60	Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2005, 16, 1035-1050.	6.1	478
61	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.7	461
62	Long-Term Outcome of Renal Transplantation from Older Donors. New England Journal of Medicine, 2006, 354, 343-352.	27.0	453
63	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews Nephrology, 2021, 17, 46-64.	9.6	444
64	Nitric Oxide Synthesis by Cultured Endothelial Cells Is Modulated by Flow Conditions. Circulation Research, 1995, 76, 536-543.	4.5	442
65	Disruption of the Ang II type 1 receptor promotes longevity in mice. Journal of Clinical Investigation, 2009, 119, 524-530.	8.2	434
66	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 1146-1155.	27.0	433
67	Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney International, 2006, 69, 2057-2063.	5.2	414
68	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	13.7	414
69	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
70	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. Journal of Immunology, 2008, 181, 3933-3946.	0.8	405
71	Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney International, 2001, 60, 831-846.	5.2	399
72	Platelet Dysfunction in Renal Failure. Seminars in Thrombosis and Hemostasis, 2004, 30, 579-589.	2.7	393

#	ARTICLE	IF	CITATIONS
73	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. <i>Kidney International</i> , 2005, 68, S57-S65.	5.2	381
74	Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. <i>Kidney International</i> , 1998, 53, 1209-1216.	5.2	378
75	Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF- κ B-dependent fashion.. <i>Journal of Clinical Investigation</i> , 1998, 101, 1905-1915.	8.2	377
76	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	7.4	376
77	Protein overload stimulates RANTES production by proximal tubular cells depending on NF- κ B activation. <i>Kidney International</i> , 1998, 53, 1608-1615.	5.2	371
78	Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. <i>New England Journal of Medicine</i> , 1993, 329, 85-89.	27.0	370
79	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. <i>Stem Cells</i> , 2008, 26, 2075-2082.	3.2	351
80	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. <i>The Lancet Global Health</i> , 2016, 4, e307-e319.	6.3	350
81	Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?. <i>Kidney International</i> , 1990, 38, 384-394.	5.2	345
82	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney International</i> , 2015, 87, 1061-1073.	5.2	342
83	Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. <i>Journal of Clinical Investigation</i> , 2015, 125, 715-726.	8.2	335
84	Early Experience with Dual Kidney Transplantation in Adults using Expanded Donor Criteria. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 2591-2598.	6.1	335
85	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. <i>Kidney International</i> , 2001, 60, 1131-1140.	5.2	334
86	STEC-HUS, atypical HUS and TTP are all diseases of complement activation. <i>Nature Reviews Nephrology</i> , 2012, 8, 622-633.	9.6	333
87	Effect of Low-Dose Aspirin on Fetal and Maternal Generation of Thromboxane by Platelets in Women at Risk for Ppregnancy-Induced Hypertension. <i>New England Journal of Medicine</i> , 1989, 321, 357-362.	27.0	326
88	Plasma clearance of nonradioactive iothexol as a measure of glomerular filtration rate.. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 6, 257-263.	6.1	316
89	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. <i>Journal of Clinical Investigation</i> , 2003, 111, 1181-1190.	8.2	315
90	Rituximab for idiopathic membranous nephropathy. <i>Lancet, The</i> , 2002, 360, 923-924.	13.7	311

#	ARTICLE	IF	CITATIONS
91	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. Journal of the American Society of Nephrology: JASN, 2013, 24, 475-486.	6.1	308
92	MicroRNAs in kidney physiology and disease. Nature Reviews Nephrology, 2015, 11, 23-33.	9.6	307
93	Child and Adolescent Health From 1990 to 2015. JAMA Pediatrics, 2017, 171, 573.	6.2	306
94	Familial haemolytic uraemic syndrome and an MCP mutation. Lancet, The, 2003, 362, 1542-1547.	13.7	303
95	URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONS. Lancet, The, 1982, 320, 1013-1015.	13.7	302
96	Transplant Renal Artery Stenosis. Journal of the American Society of Nephrology: JASN, 2004, 15, 134-141.	6.1	301
97	Transfer of Growth Factor Receptor mRNA Via Exosomes Unravels the Regenerative Effect of Mesenchymal Stem Cells. Stem Cells and Development, 2013, 22, 772-780.	2.1	300
98	Recognition and management of acute kidney injury in the International Society of Nephrology Oby25 Global Snapshot: a multinational cross-sectional study. Lancet, The, 2016, 387, 2017-2025.	13.7	299
99	Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications. Kidney International, 2005, 68, S7-S10.	5.2	295
100	Insulin-Like Growth Factor-1 Sustains Stem Cell-Mediated Renal Repair. Journal of the American Society of Nephrology: JASN, 2007, 18, 2921-2928.	6.1	294
101	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics, 2003, 12, 3385-3395.	2.9	291
102	Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood, 2005, 106, 1932-1937.	1.4	288
103	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
104	Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 1540-1546.	6.1	280
105	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2545-2558.	6.1	280
106	Podocyte Number in Normotensive Type 1 Diabetic Patients With Albuminuria. Diabetes, 2002, 51, 3083-3089.	0.6	278
107	HqMOLYTIC-URqMIC SYNDROME: DEFICIENCY OF PLASMA FACTOR(S) REGULATING PROSTACYCLIN ACTIVITY?. Lancet, The, 1978, 312, 871-872.	13.7	275
108	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275

#	ARTICLE	IF	CITATIONS
109	Sodium Intake, ACE Inhibition, and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2012, 23, 165-173.	6.1	275
110	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 412-422.	4.5	273
111	The case of complement activation in COVID-19 multiorgan impact. Kidney International, 2020, 98, 314-322.	5.2	268
112	Strategies for Making More Organs Available for Transplantation. New England Journal of Medicine, 2000, 343, 404-410.	27.0	263
113	The Molecular Basis of Familial Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2001, 12, 297-307.	6.1	263
114	Mechanisms of Disease: pre-eclampsia. Nature Clinical Practice Nephrology, 2005, 1, 98-114.	2.0	259
115	Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. Diabetes Care, 2012, 35, 2061-2068.	8.6	259
116	The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology, 2010, 6, 319-330.	9.6	252
117	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1416-1425.	6.1	252
118	Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron, 2020, 144, 213-221.	1.8	245
119	Factor H family proteins: on complement, microbes and human diseases. Biochemical Society Transactions, 2002, 30, 971-978.	3.4	244
120	Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney International, 2003, 63, 2254-2261.	5.2	244
121	Endothelin antagonists. Lancet, The, 1999, 353, 133-138.	13.7	239
122	Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney International, 2005, 68, 206-216.	5.2	239
123	Podocytopathies. Nature Reviews Disease Primers, 2020, 6, 68.	30.5	237
124	A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney International, 2006, 70, 423-431.	5.2	236
125	HUS and TTP: Variable expression of a single entity. Kidney International, 1987, 32, 292-308.	5.2	235
126	Chronic Renal Diseases: Renoprotective Benefits of Renin-Angiotensin System Inhibition. Annals of Internal Medicine, 2002, 136, 604.	3.9	235

#	ARTICLE	IF	CITATIONS
127	Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. Prostaglandins, 1980, 20, 105-110.	1.2	234
128	Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. American Journal of Kidney Diseases, 1995, 26, 934-941.	1.9	232
129	Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.. Journal of Clinical Investigation, 1990, 85, 541-549.	8.2	229
130	Mechanisms and Treatment of CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1917-1928.	6.1	225
131	Spectrum of Steroid-Resistant and Congenital Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 592-600.	4.5	225
132	Regulatory T Cells and T Cell Depletion. Journal of the American Society of Nephrology: JASN, 2007, 18, 1007-1018.	6.1	224
133	Heterogeneous nature of renal lesions in type II diabetes.. Journal of the American Society of Nephrology: JASN, 1993, 3, 1458-1466.	6.1	224
134	C3 glomerulopathy “ understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	9.6	223
135	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.4	223
136	A phase 1, single-dose study of fresolimumab, an anti-TGF- β 2 antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney International, 2011, 79, 1236-1243.	5.2	222
137	The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1083-1093.	6.1	222
138	Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ: British Medical Journal, 1998, 316, 504-509.	2.3	221
139	<i>MYO1E</i> Mutations and Childhood Familial Focal Segmental Glomerulosclerosis. New England Journal of Medicine, 2011, 365, 295-306.	27.0	221
140	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	220
141	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	13.7	218
142	Conjugated Estrogens for the Management of Bleeding Associated with Renal Failure. New England Journal of Medicine, 1986, 315, 731-735.	27.0	217
143	Interleukin-6 and RANTES in Takayasu Arteritis. Circulation, 1999, 100, 55-60.	1.6	216
144	A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney International, 1993, 44, 440-444.	5.2	215

#	ARTICLE	IF	CITATIONS
145	In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation.. Journal of the American Society of Nephrology: JASN, 1998, 9, 1213-1224.	6.1	215
146	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney International, 2002, 62, 1060-1067.	5.2	214
147	Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 1732-1746.	6.1	212
148	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 1851-1857.	6.1	208
149	Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney International, 1993, 44, 445-450.	5.2	204
150	Outcome of Renal Transplantation in Patients with Nonâ€“Shiga Toxinâ€“Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 88-99.	4.5	201
151	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	1.4	200
152	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2014, 25, 850-863.	6.1	199
153	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	11.4	199
154	Uremic Bleeding: Closing the Circle After 30 Years of Controversies?. Blood, 1999, 94, 2569-2574.	1.4	194
155	Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet, The, 2014, 383, 1844-1859.	13.7	194
156	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	6.1	194
157	Early-Childhood Membranous Nephropathy Due to Cationic Bovine Serum Albumin. New England Journal of Medicine, 2011, 364, 2101-2110.	27.0	193
158	Role of Remission Clinics in the Longitudinal Treatment of CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1213-1224.	6.1	192
159	BLEEDING IN RENAL FAILURE. Lancet, The, 1988, 331, 1205-1208.	13.7	190
160	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2011, 22, 1923-1930.	6.1	190
161	Tumor necrosis factor induces glomerular damage in the rabbit. American Journal of Pathology, 1989, 134, 419-30.	3.8	190
162	Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney International, 1993, 43, 706-711.	5.2	189

#	ARTICLE	IF	CITATIONS
163	Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. Blood, 1995, 85, 1696-1703.	1.4	189
164	Renal Vascular and Thrombotic Effects of Cyclosporine. American Journal of Kidney Diseases, 1989, 13, 261-272.	1.9	188
165	Nonviral Gene Delivery to the Rat Kidney with Polyethylenimine. Human Gene Therapy, 1997, 8, 1243-1251.	2.7	188
166	Thrombotic Microangiopathy After Kidney Transplantation. American Journal of Transplantation, 2010, 10, 1517-1523.	4.7	188
167	Estimated GFR: time for a critical appraisal. Nature Reviews Nephrology, 2019, 15, 177-190.	9.6	187
168	Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.. Journal of Clinical Investigation, 1985, 76, 1011-1018.	8.2	186
169	ACE Inhibitors to Prevent End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2001, 12, 2832-2837.	6.1	185
170	Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation. American Journal of Transplantation, 2004, 4, 1826-1835.	4.7	184
171	Hepatitis C Infection and Chronic Renal Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 207-220.	4.5	184
172	Time to abandon microalbuminuria?. Kidney International, 2006, 70, 1214-1222.	5.2	182
173	The hemolytic uremic syndrome. Kidney International, 1995, 48, 2-19.	5.2	181
174	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.7	180
175	Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study. Journal of the American Society of Nephrology: JASN, 2006, 17, S90-S97.	6.1	178
176	Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes.. Journal of the American Society of Nephrology: JASN, 1993, 4, 40-49.	6.1	178
177	Add-On Anti-TGF- β 2 Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. Journal of the American Society of Nephrology: JASN, 2003, 14, 1816-1824.	6.1	177
178	Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases, 2000, 35, 1155-1165.	1.9	174
179	Renal Progenitor Cells Contribute to Hyperplastic Lesions of Podocytopathies and Crescentic Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 2593-2603.	6.1	173
180	Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 761-767.	4.5	171

#	ARTICLE	IF	CITATIONS
181	Renal progenitors: an evolutionary conserved strategy for kidney regeneration. <i>Nature Reviews Nephrology</i> , 2013, 9, 137-146.	9.6	170
182	Insulin Resistance and Microalbuminuria. <i>Diabetes</i> , 2006, 55, 1456-1462.	0.6	169
183	Recellularization of Well-Preserved Acellular Kidney Scaffold Using Embryonic Stem Cells. <i>Tissue Engineering - Part A</i> , 2014, 20, 1486-1498.	3.1	169
184	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 682-699.	2.9	169
185	Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. <i>Kidney International</i> , 2003, 63, 1094-1103.	5.2	167
186	Life-Sparing Effect of Human Cord Blood-Mesenchymal Stem Cells in Experimental Acute Kidney Injury. <i>Stem Cells</i> , 2010, 28, 513-522.	3.2	161
187	In Chronic Nephropathies Prolonged ACE Inhibition Can Induce Remission. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 997-1006.	6.1	161
188	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. <i>Human Mutation</i> , 2007, 28, 222-234.	2.5	160
189	Maintenance Dialysis throughout the World in Years 1990 and 2010. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2621-2633.	6.1	159
190	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. <i>Kidney International</i> , 1986, 30, 488-496.	5.2	158
191	Sirolimus Therapy to Halt the Progression of ADPKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1031-1040.	6.1	157
192	How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2898-2908.	6.1	156
193	In Vivo Maturation of Functional Renal Organoids Formed from Embryonic Cell Suspensions. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1857-1868.	6.1	156
194	Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. <i>Nephron</i> , 2018, 139, 313-318.	1.8	156
195	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. <i>Lancet, The</i> , 2004, 364, 503-512.	13.7	155
196	Progression Risk, Urinary Protein Excretion, and Treatment Effects of Angiotensin-Converting Enzyme Inhibitors in Nondiabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1959-1965.	6.1	154
197	Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 940-949.	6.1	154
198	Reduced Platelet Thromboxane Formation in Uremia. EVIDENCE FOR A FUNCTIONAL CYCLOOXYGENASE DEFECT. <i>Journal of Clinical Investigation</i> , 1983, 71, 762-768.	8.2	153

#	ARTICLE	IF	CITATIONS
199	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. <i>Kidney International</i> , 1993, 43, 354-358.	5.2	153
200	Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. <i>Lancet</i> , The, 2002, 359, 1671-1672.	13.7	152
201	DAILY RENAL HYPOPERFUSION INDUCED BY CYCLOSPORINE IN PATIENTS WITH RENAL TRANSPLANTATION. <i>Transplantation</i> , 1992, 54, 56-60.	1.0	151
202	In Response to Protein Load Podocytes Reorganize Cytoskeleton and Modulate Endothelin-1 Gene. <i>American Journal of Pathology</i> , 2005, 166, 1309-1320.	3.8	151
203	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 2373-2383.	4.7	151
204	Titration of Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 932-937.	4.5	150
205	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 700-704.	2.9	150
206	Podocyte "actin dynamics in health and disease. <i>Nature Reviews Nephrology</i> , 2016, 12, 692-710.	9.6	150
207	Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis.. <i>Journal of Clinical Investigation</i> , 1985, 75, 94-101.	8.2	149
208	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , 2013, 26, 867-878.	1.6	148
209	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1237-1247.	4.5	146
210	Protein traffic activates NF- κ B gene signaling and promotes MCP-1-dependent interstitial inflammation. <i>American Journal of Kidney Diseases</i> , 2000, 36, 1226-1241.	1.9	145
211	EPSTEIN-BARR VIRUS-NEGATIVE LYMPHOPROLIFERATIVE DISORDERS IN LONG-TERM SURVIVORS AFTER HEART, KIDNEY, AND LIVER TRANSPLANT1. <i>Transplantation</i> , 2000, 69, 827-833.	1.0	144
212	Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 310-313.	6.1	144
213	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2047-2053.	0.7	143
214	Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3055-3065.	6.1	142
215	Eculizumab in a Patient with Dense-Deposit Disease. <i>New England Journal of Medicine</i> , 2012, 366, 1161-1163.	27.0	140
216	<sc>Arginine Depletion in Preeclampsia Orients Nitric Oxide Synthase Toward Oxidant Species. <i>Hypertension</i> , 2004, 43, 614-622.	2.7	139

#	ARTICLE	IF	CITATIONS
217	Hypocomplementemia Discloses Genetic Predisposition to Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. Journal of the American Society of Nephrology: JASN, 1999, 10, 281-293.	6.1	139
218	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney International, 1997, 52, 171-181.	5.2	138
219	Transforming Growth Factor- β 1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins. American Journal of Pathology, 2002, 161, 2179-2193.	3.8	138
220	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology, 2008, 45, 95-105.	2.2	136
221	Hemolytic uremic syndrome. Seminars in Immunopathology, 2014, 36, 399-420.	6.1	136
222	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.6	136
223	Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. Journal of the American Society of Nephrology: JASN, 2002, 13, 1179-89.	6.1	135
224	Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney International, 1997, 51, 1583-1589.	5.2	134
225	Pathophysiologic Implications of Reduced Podocyte Number in a Rat Model of Progressive Glomerular Injury. American Journal of Pathology, 2006, 168, 42-54.	3.8	134
226	THYMIC RECOGNITION OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES INDUCES DONOR-SPECIFIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1993, 56, 461-465.	1.0	133
227	Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. British Journal of Clinical Pharmacology, 2013, 76, 516-523.	2.4	133
228	Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats. Kidney International, 1988, 34, 481-486.	5.2	132
229	Cellular responses to protein overload: key event in renal disease progression. Current Opinion in Nephrology and Hypertension, 2004, 13, 31-37.	2.0	132
230	Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. American Journal of Kidney Diseases, 2015, 66, 359-375.	1.9	132
231	Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nature Reviews Nephrology, 2016, 12, 241-253.	9.6	132
232	Outrageous prices of orphan drugs: a call for collaboration. Lancet, The, 2018, 392, 791-794.	13.7	132
233	Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. Lancet, The, 1991, 337, 750-752.	13.7	131
234	The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney International, 2013, 84, 164-173.	5.2	131

#	ARTICLE	IF	CITATIONS
235	New therapeutics that antagonize endothelin: promises and frustrations. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 986-1001.	46.4	130
236	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. <i>Journal of Immunology</i> , 2018, 200, 2464-2478.	0.8	130
237	Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases. <i>Annals of Internal Medicine</i> , 1999, 130, 422.	3.9	129
238	Lymphomas occurring late after solid-organ transplantation. <i>Transplantation</i> , 2002, 74, 1095-1102.	1.0	129
239	Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1177-1183.	6.1	129
240	Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. <i>Journal of Hypertension</i> , 2007, 25, 1921-1926.	0.5	129
241	Treatment of Bleeding in Dialysis Patients. <i>Seminars in Dialysis</i> , 2009, 22, 279-286.	1.3	129
242	Plasma infusion for hemolytic-uremic syndrome in children: Results of a multicenter controlled trial. <i>Journal of Pediatrics</i> , 1988, 112, 284-290.	1.8	128
243	Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. <i>Kidney International</i> , 1991, 39, 1267-1273.	5.2	127
244	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , 2005, 67, 1753-1761.	5.2	126
245	Bone Marrow-Derived Mesenchymal Stem Cells Improve Islet Graft Function in Diabetic Rats. <i>Transplantation Proceedings</i> , 2009, 41, 1797-1800.	0.6	126
246	Reducing Polycystic Liver Volume in ADPKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 783-789.	4.5	126
247	Kidney regeneration. <i>Lancet, The</i> , 2010, 375, 1310-1317.	13.7	126
248	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. <i>Molecular Immunology</i> , 2016, 71, 131-142.	2.2	126
249	Combining an Antiproteinuric Approach with Mycophenolate Mofetil Fully Suppresses Progressive Nephropathy of Experimental Animals. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1542-1549.	6.1	126
250	Mutations in <i>FN1</i> cause glomerulopathy with fibronectin deposits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2538-2543.	7.1	125
251	Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. <i>Stem Cell Reviews and Reports</i> , 2013, 9, 65-79.	5.6	125
252	A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. <i>Lancet, The</i> , 2017, 390, 424-428.	13.7	125

#	ARTICLE	IF	CITATIONS
253	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 2729-2737.	6.1	125
254	MECHANISMS OF ACQUIRED THYMIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1994, 58, 125-132.	1.0	124
255	Proteinuria should be used as a surrogate in CKD. Nature Reviews Nephrology, 2012, 8, 301-306.	9.6	124
256	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nature Communications, 2017, 8, 983.	12.8	124
257	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. Blood, 1997, 90, 1558-1564.	1.4	123
258	Kidney Injury Molecule 1: In Search of Biomarkers of Chronic Tubulointerstitial Damage and Disease Progression. American Journal of Kidney Diseases, 2009, 53, 1-4.	1.9	123
259	Blocking Angiotensin II Synthesis/Activity Preserves Glomerular Nephron in Rats with Severe Nephrosis. Journal of the American Society of Nephrology: JASN, 2001, 12, 941-948.	6.1	122
260	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology, 2020, 225, 152001.	1.9	120
261	Interleukin-1 beta and tumor necrosis factor-alpha induce gene expression and production of leukocyte chemotactic factors, colony-stimulating factors, and interleukin-6 in human mesangial cells. American Journal of Pathology, 1991, 138, 991-1003.	3.8	120
262	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128.	6.1	119
263	Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).. Journal of the American Society of Nephrology: JASN, 1998, 9, 2096-2101.	6.1	119
264	Role of Insulin and Atrial Natriuretic Peptide in Sodium Retention in Insulin-Treated IDDM Patients During Isotonic Volume Expansion. Diabetes, 1990, 39, 289-298.	0.6	118
265	The losartan renal protection study â€” rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2000, 1, 328-335.	1.7	118
266	Protein Overload Induces Fractalkine Upregulation in Proximal Tubular Cells through Nuclear Factor Î² and p38 Mitogen-Activated Protein Kinase-Dependent Pathways. Journal of the American Society of Nephrology: JASN, 2003, 14, 2436-2446.	6.1	118
267	The Nrf2 pathway in the progression of renal disease. Nephrology Dialysis Transplantation, 2014, 29, i19-i24.	0.7	117
268	Treatment of membranous nephropathy: time for a paradigm shift. Nature Reviews Nephrology, 2017, 13, 563-579.	9.6	117
269	Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation. American Journal of Transplantation, 2005, 5, 1146-1150.	4.7	116
270	Rationaleâ€”Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 2005, 149, 408-413.	2.7	115

#	ARTICLE	IF	CITATIONS
271	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2007, 44, 111-122.	2.2	115
272	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. <i>European Heart Journal</i> , 2011, 32, 1493-1499.	2.2	115
273	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, F1448-F1456.	2.7	114
274	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 181-190.	11.4	114
275	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. <i>JCI Insight</i> , 2018, 3, .	5.0	114
276	Effect of Angiotensin-Converting Enzyme Inhibition on Glomerular Basement Membrane Permeability and Distribution of Zonula Occludens-1 in MWF Rats. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 477-489.	6.1	114
277	Continuum of Renoprotection with Losartan at All Stages of Type 2 Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL Trial Results. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 3117-3125.	6.1	112
278	Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. <i>Kidney International</i> , 2004, 65, 2193-2200.	5.2	112
279	Human Amniotic Fluid Stem Cell Preconditioning Improves Their Regenerative Potential. <i>Stem Cells and Development</i> , 2012, 21, 1911-1923.	2.1	112
280	Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. <i>BMJ Open</i> , 2014, 4, e003536.	1.9	112
281	Bleeding in Renal Failure: Altered Platelet Function in Chronic Uraemia only Partially Corrected by Haemodialysis. <i>Nephron</i> , 1978, 22, 347-353.	1.8	111
282	Monogenic diseases that can be cured by liver transplantation. <i>Journal of Hepatology</i> , 2013, 59, 595-612.	3.7	111
283	Adaptations and Lessons in the Province of Bergamo. <i>New England Journal of Medicine</i> , 2020, 382, e71.	27.0	111
284	Endothelins in the control of cardiovascular and renal function. <i>Lancet, The</i> , 1993, 342, 589-593.	13.7	110
285	Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. <i>Lancet, The</i> , 2002, 359, 663-666.	13.7	110
286	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.. <i>Journal of Clinical Investigation</i> , 1990, 86, 1768-1771.	8.2	110
287	Platelet hyperaggregability and the nephrotic syndrome. <i>Thrombosis Research</i> , 1979, 16, 345-354.	1.7	109
288	Drug-Induced Thrombotic Microangiopathy. <i>Drug Safety</i> , 2001, 24, 491-501.	3.2	109

#	ARTICLE	IF	CITATIONS
289	Proximal tubular cells promote fibrogenesis by TGF- β -mediated induction of peritubular myofibroblasts. <i>Kidney International</i> , 2002, 61, 2066-2077.	5.2	109
290	Favorable Long-Term Outcome after Liver-Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation. <i>American Journal of Transplantation</i> , 2006, 6, 1948-1952.	4.7	109
291	A Novel Strategy to Enhance Mesenchymal Stem Cell Migration Capacity and Promote Tissue Repair in an Injury Specific Fashion. <i>Cell Transplantation</i> , 2013, 22, 423-436.	2.5	109
292	Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 1948-1955.	6.1	109
293	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. <i>American Journal of Pathology</i> , 2005, 167, 1173-1181.	3.8	108
294	The pathophysiology and management of thrombotic thrombocytopenic purpura. <i>European Journal of Haematology</i> , 1996, 56, 191-207.	2.2	108
295	Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. <i>Laboratory Investigation</i> , 1982, 46, 16-23.	3.7	108
296	Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.. <i>Diabetes</i> , 1998, 47, 450-456.	0.6	107
297	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. <i>Blood</i> , 2012, 120, 440-448.	1.4	107
298	ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. <i>Kidney International</i> , 2006, 69, 1124-1130.	5.2	106
299	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. <i>Blood</i> , 2012, 119, 3269-3275.	1.4	106
300	Prostacyclin and human foetal circulation. <i>Prostaglandins</i> , 1979, 18, 341-348.	1.2	105
301	Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. <i>Kidney International</i> , 1991, 40, 243-250.	5.2	105
302	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF- κ B dependent up-regulation of IL-8 and MCP-11. <i>Kidney International</i> , 2002, 62, 846-856.	5.2	105
303	RISK OF NONMELANOMA SKIN CANCER IN ITALIAN ORGAN TRANSPLANT RECIPIENTS. A REGISTRY-BASED STUDY. <i>Transplantation</i> , 2000, 70, 1479-1484.	1.0	104
304	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. <i>Kidney International</i> , 2002, 61, 1635-1645.	5.2	103
305	Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. <i>CardioRenal Medicine</i> , 2012, 2, 1-10.	1.9	103
306	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	7.4	103

#	ARTICLE	IF	CITATIONS
307	Mycophenolate Mofetil versus Azathioprine for Prevention of Chronic Allograft Dysfunction in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2007, 18, 1973-1985.	6.1	102
308	Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Translational Research, 2013, 161, 73-84.	5.0	102
309	Challenges to achieving clinical transplantation tolerance. Journal of Clinical Investigation, 2001, 108, 943-948.	8.2	101
310	Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk. Hypertension, 2009, 54, 567-574.	2.7	101
311	Inhibiting Angiotensin-Converting Enzyme Promotes Renal Repair by Limiting Progenitor Cell Proliferation and Restoring the Glomerular Architecture. American Journal of Pathology, 2011, 179, 628-638.	3.8	100
312	Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. Journal of the American Society of Nephrology: JASN, 1990, 1, 76-83.	6.1	100
313	Adriamycin-Induced Glomerulosclerosis in the Rat. American Journal of Kidney Diseases, 1986, 7, 12-19.	1.9	99
314	Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. American Journal of Kidney Diseases, 1996, 27, 416-423.	1.9	99
315	The Aggravating Mechanisms of Aldosterone on Kidney Fibrosis. Journal of the American Society of Nephrology: JASN, 2008, 19, 1459-1462.	6.1	99
316	Antiproteinuric Therapy while Preventing the Abnormal Protein Traffic in Proximal Tubule Abrogates Protein- and Complement-Dependent Interstitial Inflammation in Experimental Renal Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 804-813.	6.1	99
317	Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney.. Journal of the American Society of Nephrology: JASN, 1996, 7, 653-660.	6.1	98
318	PROSTACYCLIN-LIKE ACTIVITY AND BLEEDING IN RENAL FAILURE. Lancet, The, 1977, 310, 1195-1197.	13.7	97
319	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	97
320	Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence. American Journal of Transplantation, 2013, 13, 266-274.	4.7	97
321	Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition.. Journal of Clinical Investigation, 1987, 79, 1788-1797.	8.2	97
322	The nephropathy of non-insulin-dependent diabetes. Journal of the American Society of Nephrology: JASN, 1998, 9, 2336-2343.	6.1	96
323	Thromboxane synthesis and action within the kidney. Kidney International, 1992, 41, 1483-1493.	5.2	95
324	Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Journal of Hypertension, 2006, 24, 403-408.	0.5	94

#	ARTICLE	IF	CITATIONS
325	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. Transplantation, 2007, 84, 956-964.	1.0	94
326	Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. Thrombosis Research, 1983, 32, 373-379.	1.7	93
327	Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney International, 1999, 55, 674-685.	5.2	93
328	Reversible Activation Defect of the Platelet Glycoprotein IIb-IIIa Complex in Patients With Uremia. American Journal of Kidney Diseases, 1993, 22, 668-676.	1.9	92
329	Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood, 1995, 86, 4553-4558.	1.4	92
330	Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood, 2001, 98, 1828-1835.	1.4	92
331	Shigatoxin-Induced Endothelin-1 Expression in Cultured Podocytes Autocrinally Mediates Actin Remodeling. American Journal of Pathology, 2006, 169, 1965-1975.	3.8	92
332	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International, 2006, 69, 1675-1682.	5.2	92
333	Podocyte Repopulation Contributes to Regression of Glomerular Injury Induced by Ace Inhibition. American Journal of Pathology, 2009, 174, 797-807.	3.8	92
334	Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney International, 2014, 86, 1244-1252.	5.2	91
335	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.7	91
336	Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients. Journal of the American Society of Nephrology: JASN, 2000, 11, 88-96.	6.1	91
337	Progressive glomerular injury in the MWF rat is predicted by inborn nephron deficit.. Journal of the American Society of Nephrology: JASN, 1998, 9, 1399-1406.	6.1	91
338	Diets For Patients With Chronic Kidney Disease, Still Worth Prescribing. Journal of the American Society of Nephrology: JASN, 2004, 15, 234-237.	6.1	90
339	Imaging of the Porous Ultrastructure of the Glomerular Epithelial Filtration Slit. Journal of the American Society of Nephrology: JASN, 2010, 21, 2081-2089.	6.1	90
340	Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. American Journal of Physiology - Renal Physiology, 2013, 304, F808-F819.	2.7	90
341	Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. Nephrology Dialysis Transplantation, 2015, 30, 706-712.	0.7	90
342	Italy's first wave of the COVID-19 pandemic has ended: no excess mortality in May, 2020. Lancet, The, 2020, 396, e27-e28.	13.7	90

#	ARTICLE	IF	CITATIONS
343	A Novel Atypical Hemolytic Uremic Syndromeâ€”Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor Hâ€”Dependent Complement Regulation. Journal of the American Society of Nephrology: JASN, 2015, 26, 209-219.	6.1	89
344	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. Scientific Reports, 2017, 7, 11518.	3.3	89
345	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complexâ€”Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	6.1	89
346	Proteasomal Processing of Albumin by Renal Dendritic Cells Generates Antigenic Peptides. Journal of the American Society of Nephrology: JASN, 2009, 20, 123-130.	6.1	88
347	Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. American Journal of Physiology - Renal Physiology, 2012, 303, F1370-F1381.	2.7	88
348	Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury. Scientific Reports, 2015, 5, 8826.	3.3	88
349	Long-term follow-up of recovered patients with COVID-19. Lancet, The, 2021, 397, 173-175.	13.7	88
350	Prevention of chronic kidney and vascular disease: Toward global health equityâ€”The Bellagio 2004 Declaration. Kidney International, 2005, 68, S1-S6.	5.2	86
351	Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thrombosis and Haemostasis, 2006, 95, 212-220.	3.4	86
352	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics, 2007, 8, 1127-1141.	1.3	86
353	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.	2.7	86
354	Thrombotic Thrombocytopenic Purpura and Related Disorders. Hematology/Oncology Clinics of North America, 1990, 4, 219-241.	2.2	85
355	Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Renoprotection in Diabetic and Nondiabetic Nephropathies. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1511-1525.	4.5	85
356	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.4	85
357	THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE. Transplantation, 1992, 54, 775-779.	1.0	84
358	MicroRNA-324-3p Promotes Renal Fibrosis and Is a Target of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2012, 23, 1496-1505.	6.1	84
359	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney International, 2014, 86, 246-250.	5.2	84
360	Rituximab for Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 738-748.	4.5	83

#	ARTICLE	IF	CITATIONS
361	Successful Liver-Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H. American Journal of Transplantation, 2007, 8, 071105081616017-???.	4.7	83
362	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	4.4	83
363	Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis.. Journal of the American Society of Nephrology: JASN, 1998, 9, 1202-1212.	6.1	83
364	Plasmapheresis in the treatment of acute renal failure in multiple myeloma. American Journal of Medicine, 1979, 66, 684-688.	1.5	82
365	Permselective Dysfunction of Podocyte-Podocyte Contact upon Angiotensin II Unravels the Molecular Target for Renoprotective Intervention. American Journal of Pathology, 2006, 168, 1073-1085.	3.8	82
366	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). American Journal of Nephrology, 2013, 37, 212-222.	3.1	82
367	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	1.4	82
368	Proteinuria and Phenotypic Change of Proximal Tubular Cells. Journal of the American Society of Nephrology: JASN, 2003, 14, S36-S41.	6.1	81
369	Tackling the Shortage of Donor Kidneys: How to Use the Best that We Have. American Journal of Nephrology, 2003, 23, 245-259.	3.1	81
370	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis, 2005, 93, 443-452.	3.4	81
371	Timed Urine Collections Are Not Needed to Measure Urine Protein Excretion in Clinical Practice. American Journal of Kidney Diseases, 2006, 47, 1-7.	1.9	81
372	The Complement Factor H R1210C Mutation Is Associated With Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2008, 19, 639-646.	6.1	81
373	Prevention of Transplant Rejection. Drugs, 1997, 54, 533-570.	10.9	80
374	ACE Gene Polymorphism and Losartan Treatment in Type 2 Diabetic Patients With Nephropathy. Journal of the American Society of Nephrology: JASN, 2008, 19, 771-779.	6.1	80
375	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1717-1724.	6.1	80
376	Pancreas and kidney/pancreas transplants: experimental medicine or real improvement?. Lancet, The, 1994, 343, 27-31.	13.7	79
377	Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study. Nephron Clinical Practice, 2010, 115, c154-c160.	2.3	79
378	Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney International, 1988, 34, 853-858.	5.2	78

#	ARTICLE	IF	CITATIONS
379	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: Implications for dialysis hypotension. <i>American Journal of Kidney Diseases</i> , 1998, 32, 115-124.	1.9	78
380	Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice.. <i>Journal of the American Society of Nephrology: JASN</i> , 1997, 8, 720-729.	6.1	78
381	Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy1. <i>Kidney International</i> , 1998, 54, 353-359.	5.2	77
382	Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 936-953.	46.4	77
383	Key fibrogenic mediators: old players. Reninâ€“angiotensin system. <i>Kidney International Supplements</i> , 2014, 4, 58-64.	14.2	77
384	Nephropathy of type-2 diabetes mellitus.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 2157-2169.	6.1	77
385	Effect of angiotensin II antagonism on the regression of kidney disease in the rat. <i>Kidney International</i> , 2002, 62, 885-894.	5.2	76
386	Transcriptional Regulation of Nephric Gene by Peroxisome Proliferatorâ€“Activated Receptor-Î³ Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1624-1632.	6.1	76
387	Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. <i>Thrombosis Research</i> , 1978, 13, 1007-1015.	1.7	75
388	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. <i>Kidney International</i> , 2000, 57, 274-281.	5.2	75
389	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. <i>Clinical Transplantation</i> , 2001, 15, 402-409.	1.6	75
390	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. <i>Journal of Immunology</i> , 2013, 191, 2818-2828.	0.8	75
391	Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor. <i>PLoS ONE</i> , 2013, 8, e70775.	2.5	75
392	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. <i>American Journal of Kidney Diseases</i> , 1997, 29, 254-264.	1.9	74
393	Application of newer clearance techniques for the determination of glomerular filtration rate. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 675-680.	2.0	74
394	Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S58-S63.	6.1	74
395	Thrombotic Thrombocytopenic Purpura: Evidence That Infusion Rather Than Removal of Plasma Induces Remission of the Disease. <i>American Journal of Kidney Diseases</i> , 1993, 21, 314-318.	1.9	73
396	Cardiovascular risk assessment in low-resource settings. <i>Journal of Hypertension</i> , 2014, 32, 951-960.	0.5	73

#	ARTICLE	IF	CITATIONS
397	Recombinant Human Erythropoietin to Correct Uremic Bleeding. American Journal of Kidney Diseases, 1991, 18, 44-49.	1.9	72
398	Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. American Journal of Transplantation, 2005, 5, 2937-2944.	4.7	72
399	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-464.	3.4	72
400	Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Current Opinion in Nephrology and Hypertension, 1995, 4, 339-342.	2.0	71
401	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney International, 1998, 53, 726-734.	5.2	71
402	ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. American Journal of Kidney Diseases, 2000, 35, 381-391.	1.9	71
403	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney International, 2006, 70, 97-103.	5.2	71
404	Chronic kidney disease: a research and public health priority. Nephrology Dialysis Transplantation, 2012, 27, iii19-iii26.	0.7	71
405	An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	71
406	Treatment of the hemolytic uremic syndrome with plasma. Clinical Nephrology, 1979, 12, 279-84.	0.7	71
407	Radial Artery Remodeling in Response to Shear Stress Increase Within Arteriovenous Fistula for Hemodialysis Access. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 95-102.	1.7	70
408	Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats. American Journal of Pathology, 2007, 170, 1165-1177.	3.8	70
409	Mesenchymal stromal cells to promote solid organ transplantation tolerance. Current Opinion in Organ Transplantation, 2013, 18, 51-58.	1.6	70
410	<i>Sirt3</i> Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by <i>Opa1</i> Gene Transfer. Antioxidants and Redox Signaling, 2019, 31, 1255-1271.	5.4	70
411	Renal function at hospital admission as a prognostic factor in adult hemolytic uremic syndrome. The Italian Registry of Haemolytic Uremic Syndrome.. Journal of the American Society of Nephrology: JASN, 1992, 2, 1640-1644.	6.1	70
412	Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. Kidney International, 1988, 34, 164-174.	5.2	69
413	Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?. Nephrology Dialysis Transplantation, 2000, 15, 1900-1902.	0.7	69
414	Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders. Hematology American Society of Hematology Education Program, 2001, 2001, 282-305.	2.5	68

#	ARTICLE	IF	CITATIONS
415	Long-Term Renal Allograft Function on a Tacrolimus-Based, Pred-Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF+.. American Journal of Transplantation, 2006, 6, 1617-1623.	4.7	68
416	Effective CKD Care in European Countries: Challenges and Opportunities for Health Policy. American Journal of Kidney Diseases, 2015, 65, 15-25.	1.9	68
417	MODERATE DOSES OF ASPIRIN AND RISK OF BLEEDING IN RENAL FAILURE. Lancet, The, 1986, 327, 414-416.	13.7	67
418	Nephrotoxic aspects of cyclosporine. Transplantation Proceedings, 2004, 36, S234-S239.	0.6	67
419	Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial. Journal of the American Society of Nephrology: JASN, 2006, 17, 3472-3481.	6.1	67
420	Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study. American Journal of Nephrology, 2011, 33, 461-468.	3.1	67
421	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney International, 2013, 84, 1237-1245.	5.2	67
422	Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. Blood, 1995, 85, 1696-703.	1.4	67
423	Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. Thrombosis Research, 1978, 13, 531-536.	1.7	66
424	Increased renal endothelin production in rats with reduced renal mass. American Journal of Physiology - Renal Physiology, 1991, 260, F331-F339.	2.7	66
425	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. American Journal of Kidney Diseases, 2002, 40, 783-793.	1.9	66
426	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). Transplantation, 2010, 90, 124-126.	1.0	66
427	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes, 2017, 66, 75-86.	0.6	66
428	Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started.. Journal of the American Society of Nephrology: JASN, 1994, 5, 1139-1146.	6.1	66
429	Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thrombosis Research, 1979, 16, 517-525.	1.7	65
430	Haemolytic uraemic syndrome: therapeutic effect of plasma infusion.. BMJ: British Medical Journal, 1982, 285, 1304-1306.	2.3	65
431	The Role of Protein Traffic in the Progression of Renal Diseases. Annual Review of Medicine, 2000, 51, 315-327.	12.2	65
432	Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies. Circulation, 2003, 107, 586-592.	1.6	65

#	ARTICLE	IF	CITATIONS
433	Generation of functional podocytes from human induced pluripotent stem cells. <i>Stem Cell Research</i> , 2016, 17, 130-139.	0.7	65
434	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	1.0	64
435	Membranous Nephropathy Associated With IgG4-Related Disease. <i>American Journal of Kidney Diseases</i> , 2011, 58, 272-275.	1.9	64
436	CTLA4Ig Gene Transfer Prolongs Survival and Induces Donor-Specific Tolerance in a Rat Renal Allograft. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 747-752.	6.1	64
437	The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 2308-2317.	6.1	64
438	Thymic Dendritic Cells Express Inducible Nitric Oxide Synthase and Generate Nitric Oxide in Response to Self- and Alloantigens. <i>Journal of Immunology</i> , 2000, 164, 4649-4658.	0.8	63
439	Size regulation of von Willebrand factorâ€‘mediated platelet thrombi by ADAMTS13 in flowing blood. <i>Blood</i> , 2006, 107, 1943-1950.	1.4	63
440	Complement-Mediated Dysfunction of Glomerular Filtration Barrier Accelerates Progressive Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1158-1167.	6.1	63
441	Cardiovascular complications in atypical haemolytic uraemic syndrome. <i>Nature Reviews Nephrology</i> , 2014, 10, 174-180.	9.6	63
442	Î²-Arrestin-1 Drives Endothelin-1â€‘Mediated Podocyte Activation and Sustains Renal Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 523-533.	6.1	63
443	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 239-254.	0.7	63
444	Long-Term Treatment With Either Enalapril or Nitrendipine Stabilizes Albuminuria and Increases Glomerular Filtration Rate in Non- Insulin-Dependent Diabetic Patients. <i>American Journal of Kidney Diseases</i> , 1994, 24, 753-761.	1.9	62
445	ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. <i>American Journal of Kidney Diseases</i> , 1999, 34, 626-632.	1.9	62
446	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. <i>Journal of Hypertension</i> , 2011, 29, 207-216.	0.5	62
447	Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. <i>Pediatric Nephrology</i> , 2015, 30, 167-172.	1.7	62
448	Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , 2002, 61, 1064-1078.	5.2	61
449	Involvement of renal tubular tollâ€‘like receptor 9 in the development of tubulointerstitial injury in systemic lupus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1569-1578.	6.7	61
450	Prevention and Treatment of Pregnancy-Associated Hypertension: What Have We Learned in the Last 10 Years?. <i>American Journal of Kidney Diseases</i> , 1991, 18, 285-305.	1.9	60

#	ARTICLE	IF	CITATIONS
451	Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN). <i>Kidney International</i> , 2004, 66, S90-S96.	5.2	60
452	Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 591-596.	4.5	60
453	Successful Split Liver-Kidney Transplant for Factor H Associated Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 201-206.	4.5	60
454	ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1404-1415.	6.1	60
455	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2009, 54, 59-69.	1.9	60
456	Maternal and environmental risk factors for neonatal AKI and its long-term consequences. <i>Nature Reviews Nephrology</i> , 2018, 14, 688-703.	9.6	60
457	Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. <i>Translational Research</i> , 1992, 120, 229-38.	2.3	60
458	Cyclosporin-induced endothelial cell injury. <i>Laboratory Investigation</i> , 1986, 55, 455-62.	3.7	60
459	Glomerular hyperfiltration. <i>Nature Reviews Nephrology</i> , 2022, 18, 435-451.	9.6	60
460	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. <i>American Journal of Hematology</i> , 1989, 31, 32-35.	4.1	59
461	Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. <i>Kidney International</i> , 1995, 48, 155-162.	5.2	59
462	Hemolytic Uremic Syndrome: A Factor H Mutation (E1172Stop) Causes Defective Complement Control at the Surface of Endothelial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 506-514.	6.1	59
463	Angiotensin receptors as determinants of life span. <i>Pflugers Archiv European Journal of Physiology</i> , 2010, 459, 325-332.	2.8	59
464	Nature and Mediators of Parietal Epithelial Cell Activation in Glomerulonephritides of Human and Rat. <i>American Journal of Pathology</i> , 2013, 183, 1769-1778.	3.8	59
465	Renal progenitors in non-diabetic and diabetic nephropathies. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 13-20.	7.1	59
466	Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 64-71.	4.4	59
467	Nephropathic nature of proteinuria. <i>Current Opinion in Nephrology and Hypertension</i> , 1999, 8, 655-663.	2.0	59
468	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. <i>Blood</i> , 1989, 74, 978-983.	1.4	59

#	ARTICLE	IF	CITATIONS
469	Computational Fluid Dynamics of a Vascular Access Case for Hemodialysis. <i>Journal of Biomechanical Engineering</i> , 2001, 123, 284-292.	1.3	58
470	From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. <i>American Journal of Transplantation</i> , 2004, 4, 299-310.	4.7	58
471	A COMPARATIVE PROSPECTIVE STUDY OF TWO AVAILABLE SOLUTIONS FOR KIDNEY AND LIVER PRESERVATION. <i>Transplantation</i> , 2004, 77, 1540-1545.	1.0	58
472	The Regenerative Potential of Stem Cells in Acute Renal Failure. <i>Cell Transplantation</i> , 2006, 15, 111-117.	2.5	58
473	Burden of CKD, Proteinuria, and Cardiovascular Risk Among Chinese, Mongolian, and Nepalese Participants in the International Society of Nephrology Screening Programs. <i>American Journal of Kidney Diseases</i> , 2010, 56, 915-927.	1.9	58
474	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 704-712.	2.0	58
475	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1359.	4.8	58
476	Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products.. <i>Journal of the American Society of Nephrology: JASN</i> , 1991, 2, 57-69.	6.1	58
477	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. <i>Kidney International</i> , 1989, 36, 57-64.	5.2	57
478	Evidence against a pathogenetic role for endothelin in pre-eclampsia. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1992, 99, 798-802.	2.3	57
479	Malignant vascular disease of the kidney: Nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. <i>American Journal of Kidney Diseases</i> , 1996, 27, 459-475.	1.9	57
480	How renal cytokines and growth factors contribute to renal disease progression. <i>American Journal of Kidney Diseases</i> , 2001, 37, S21-S24.	1.9	57
481	Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. <i>American Journal of Transplantation</i> , 2004, 4, 1345-1351.	4.7	57
482	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. <i>Blood</i> , 2005, 106, 925-928.	1.4	57
483	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. <i>American Journal of Kidney Diseases</i> , 2018, 71, 91-101.	1.9	57
484	Glomerular filtration rate determined from a single plasma sample after intravenous iohexol injection. <i>Journal of the American Society of Nephrology: JASN</i> , 1996, 7, 2689-2693.	6.1	57
485	Protein Overload Activates Proximal Tubular Cells to Release Vasoactive and Inflammatory Mediators. <i>Nephron Experimental Nephrology</i> , 1999, 7, 420-428.	2.2	56
486	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. <i>Clinical Chemistry</i> , 2001, 47, 1679-1687.	3.2	56

#	ARTICLE	IF	CITATIONS
487	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , 2009, 76, 960-967.	5.2	56
488	Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. <i>European Heart Journal</i> , 2011, 32, 2476-2478.	2.2	56
489	Distinct cardiac and renal effects of ET _A receptor antagonist and ACE inhibitor in experimental type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, F1114-F1123.	2.7	56
490	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. <i>Journal of Immunology</i> , 2017, 199, 1021-1040.	0.8	56
491	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. <i>Lancet Oncology</i> , 2021, 22, 558-570.	10.7	56
492	Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. <i>Journal of the American Society of Nephrology: JASN</i> , 1996, 7, 594-601.	6.1	56
493	Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. <i>Journal of the American Society of Nephrology: JASN</i> , 1997, 8, 647-652.	6.1	56
494	Antibody-mediated extraction/negative-ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine. <i>Analytical Biochemistry</i> , 1987, 163, 255-262.	2.4	55
495	Indomethacin reduces proteinuria in passive Heymann nephritis in rats. <i>Kidney International</i> , 1987, 31, 1335-1343.	5.2	55
496	Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 1998, 31, 453-463.	1.9	55
497	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. <i>Kidney International</i> , 2005, 67, S2-S7.	5.2	55
498	Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 362-375.	6.1	55
499	Renal epidemiology. The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 3034-3036.	0.7	54
500	MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. <i>Diabetologia</i> , 2017, 60, 1114-1125.	6.3	54
501	Mesenchymal Stromal Cells for Transplant Tolerance. <i>Frontiers in Immunology</i> , 2019, 10, 1287.	4.8	54
502	Nephrotoxicity of increased glomerular protein traffic. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 304-312.	0.7	53
503	Prevention programmes of progressive renal disease in developing nations (Review Article). <i>Nephrology</i> , 2006, 11, 321-328.	1.6	53
504	Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1147-1155.	4.5	53

#	ARTICLE	IF	CITATIONS
505	Effects of Rituximab on Morphofunctional Abnormalities of Membranous Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1652-1659.	4.5	53
506	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. Transplantation, 1997, 63, 1508-1514.	1.0	53
507	Bleeding in renal failure: is von Willebrand factor implicated?. BMJ: British Medical Journal, 1977, 2, 359-361.	2.3	52
508	Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. Journal of Thrombosis and Haemostasis, 2003, 1, 632-634.	3.8	52
509	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney International, 2004, 66, 1959-1965.	5.2	52
510	Thrombotic Thrombocytopenic Purpura-Then and Now. Seminars in Thrombosis and Hemostasis, 2006, 32, 081-089.	2.7	52
511	Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. Journal of the American Society of Nephrology: JASN, 2014, 25, 1786-1798.	6.1	52
512	Experimental Evaluation of Kidney Regeneration by Organ Scaffold Recellularization. Scientific Reports, 2017, 7, 43502.	3.3	52
513	Renal injury induced by long-term administration of cyclosporin A to rats. American Journal of Pathology, 1987, 127, 569-79.	3.8	52
514	Effect of short-term cyclosporine administration in rats on renin-angiotensin and thromboxane A2: possible relevance to the reduction in glomerular filtration rate. Journal of Pharmacology and Experimental Therapeutics, 1986, 239, 229-35.	2.5	52
515	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood, 1989, 74, 978-983.	1.4	51
516	Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. American Journal of Kidney Diseases, 1996, 27, 34-41.	1.9	51
517	Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney International, 1999, 55, 984-994.	5.2	51
518	Correction of Anemia " Payoffs and Problems. New England Journal of Medicine, 2006, 355, 2144-2146.	27.0	51
519	Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. American Journal of Transplantation, 2013, 13, 2201-2206.	4.7	51
520	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2015, 26, 1205-1214.	6.1	51
521	Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells. Journal of the American Society of Nephrology: JASN, 2016, 27, 1400-1411.	6.1	51
522	Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. Scientific Reports, 2020, 10, 8418.	3.3	51

#	ARTICLE	IF	CITATIONS
523	Low-protein diet prevents glomerular damage in adriamycin-treated rats. <i>Kidney International</i> , 1985, 28, 21-27.	5.2	50
524	Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. <i>American Journal of Physiology - Renal Physiology</i> , 1986, 251, F581-F587.	2.7	50
525	Human placenta expresses endothelin gene and corresponding protein is excreted in urine in increasing amounts during normal pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 844-848.	1.3	50
526	Kidney failure: aims for the next 10 years and barriers to success. <i>Lancet, The</i> , 2013, 382, 353-362.	13.7	50
527	Diets for patients with chronic kidney disease, should we reconsider?. <i>BMC Nephrology</i> , 2016, 17, 80.	1.8	50
528	Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. <i>Kidney International</i> , 1987, 31, 1248-1256.	5.2	49
529	Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats. <i>Diabetes</i> , 1992, 41, 533-538.	0.6	49
530	Increased nitric oxide formation in recurrent thrombotic microangiopathies: A possible mediator of microvascular injury. <i>American Journal of Kidney Diseases</i> , 1996, 27, 790-796.	1.9	49
531	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. <i>Kidney International</i> , 2001, 60, 653-663.	5.2	49
532	Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F1203-F1211.	2.7	49
533	Podocyte dysfunction in atypical haemolytic uraemic syndrome. <i>Nature Reviews Nephrology</i> , 2015, 11, 245-252.	9.6	49
534	Plasma Exchange in Children With Hemolytic-Uremic Syndrome at Risk of Poor Outcome. <i>American Journal of Kidney Diseases</i> , 1993, 22, 264-266.	1.9	48
535	PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. <i>American Journal of Physiology - Cell Physiology</i> , 1995, 269, C42-C47.	4.6	48
536	The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. <i>BMC Nephrology</i> , 2016, 17, 141.	1.8	48
537	Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. <i>Kidney International</i> , 1996, 49, 282-286.	5.2	47
538	The future of renoprotection: Frustration and promises. <i>Kidney International</i> , 2003, 64, 1947-1955.	5.2	47
539	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1011-1019.	4.5	47
540	Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. <i>Lancet, The</i> , 2015, 385, 867-874.	13.7	47

#	ARTICLE	IF	CITATIONS
541	Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. <i>American Journal of Transplantation</i> , 2017, 17, 3159-3171.	4.7	47
542	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	5.2	47
543	THROMBOTIC TENDENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Lancet, The</i> , 1981, 317, 719.	13.7	46
544	Plasmatic regulation of vascular prostacyclin in pregnancy.. <i>BMJ: British Medical Journal</i> , 1981, 282, 512-514.	2.3	46
545	Proteinuria as a Mediator of Tubulointerstitial Injury. <i>Kidney and Blood Pressure Research</i> , 1999, 22, 37-46.	2.0	46
546	Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. <i>Kidney International</i> , 2005, 68, S87-S94.	5.2	46
547	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. <i>Arthritis and Rheumatism</i> , 2007, 56, 1629-1637.	6.7	46
548	The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts. <i>Journal of Immunology</i> , 2009, 183, 4249-4260.	0.8	46
549	Sirolimus for calcineurin inhibitors in organ transplantation: contra. <i>Kidney International</i> , 2010, 78, 1068-1074.	5.2	46
550	Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study. <i>PLoS ONE</i> , 2012, 7, e32533.	2.5	46
551	Rare diseases and effective treatments: are we delivering?. <i>Lancet, The</i> , 2015, 385, 750-752.	13.7	46
552	C3a receptor blockade protects podocytes from injury in diabetic nephropathy. <i>JCI Insight</i> , 2020, 5, .	5.0	46
553	Pathophysiology and management of thrombotic microangiopathies. <i>Journal of Nephrology</i> , 1998, 11, 300-10.	2.0	46
554	PROSTACYCLIN GENERATION BY CULTURED ENDOTHELIAL CELLS IN HÅ†MOLYTIC URÅ†MIC SYNDROME. <i>Lancet, The</i> , 1980, 315, 656-657.	13.7	45
555	Angiotensin-Converting Enzyme nhibition Prevents Glomerular-Tubule Disconnection and Atrophy in Passive Heymann Nephritis, an Effect Not Observed with a Calcium Antagonist. <i>American Journal of Pathology</i> , 2001, 159, 1743-1750.	3.8	45
556	Biocompatibility and function of microencapsulated pancreatic islets. <i>Acta Biomaterialia</i> , 2006, 2, 221-227.	8.3	45
557	Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis. <i>American Journal of Nephrology</i> , 2011, 34, 367-372.	3.1	45
558	Acute renal failure: an unacceptable death sentence globally. <i>Lancet, The</i> , 2013, 382, 2041-2042.	13.7	45

#	ARTICLE	IF	CITATIONS
559	Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?. American Journal of Physiology - Renal Physiology, 2016, 310, F335-F341.	2.7	45
560	Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1022-1030.e4.	4.4	45
561	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	45
562	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Frontiers in Immunology, 2022, 13, 827146.	4.8	45
563	Angiotensin II Blockade Limits Tubular Protein Overreabsorption and the Consequent Upregulation of Endothelin 1 Gene in Experimental Membranous Nephropathy. Nephron Experimental Nephrology, 1998, 6, 121-131.	2.2	44
564	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	44
565	Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. Seminars in Nephrology, 2004, 24, 131-140.	1.6	44
566	Progression of chronic kidney disease: insights from animal models. Current Opinion in Nephrology and Hypertension, 2006, 15, 250-257.	2.0	44
567	Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cell Targeted Therapy in Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 546-554.	4.5	44
568	Is the ONTARGET renal substudy actually off target?. Nature Reviews Nephrology, 2009, 5, 436-437.	9.6	44
569	Challenges to achieving clinical transplantation tolerance. Journal of Clinical Investigation, 2001, 108, 943-948.	8.2	44
570	Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	44
571	PARATHYROID HORMONE INHIBITS HUMAN PLATELET FUNCTION. Lancet, The, 1981, 318, 1321-1323.	13.7	43
572	Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with $\alpha 3$ chain of type IV collagen. Kidney International, 1998, 54, 1550-1561.	5.2	43
573	Halting the Progression of Chronic Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, S190-S195.	6.1	43
574	DOPPLER ULTRASONOGRAPHY IN POSTTRANSPLANT RENAL ARTERY STENOSIS. Transplantation, 2003, 76, 147-153.	1.0	43
575	Beneficial Effect of TGF β 2 Antagonism in Treating Diabetic Nephropathy Depends on When Treatment Is Started. Nephron Experimental Nephrology, 2006, 104, e158-e168.	2.2	43
576	The role of chemokines in progressive renal disease. Frontiers in Bioscience - Landmark, 2009, Volume, 1815.	3.0	43

#	ARTICLE	IF	CITATIONS
577	Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease. <i>Nephron</i> , 2015, 129, 52-61.	1.8	43
578	Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?. <i>Nephron Clinical Practice</i> , 2015, 128, 261-269.	2.3	43
579	Mesenchymal Stem Cells in Kidney Repair. <i>Methods in Molecular Biology</i> , 2016, 1416, 89-107.	0.9	43
580	Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells. <i>Scientific Reports</i> , 2019, 9, 8001.	3.3	43
581	Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. <i>Diabetologia</i> , 1996, 39, 1625-1628.	6.3	42
582	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. <i>American Journal of Kidney Diseases</i> , 1999, 33, 746-753.	1.9	42
583	Insulin Resistance and Proliferative Retinopathy: A Cross-Sectional, Case-Control Study in 115 Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4371-4376.	3.6	42
584	Polymorphisms of EDNRB, ATG, and ACE genes in salt-sensitive hypertensionThis article is one of a selection of papers published in the special issue (part 2 of 2) on Forefronts in Endothelin.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2008, 86, 505-510.	1.4	42
585	Ethical issues in dialysis therapy. <i>Lancet, The</i> , 2017, 389, 1851-1856.	13.7	42
586	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , 2019, 16, e1002777.	8.4	42
587	Albuminuria as early test for vascular disease. <i>Lancet, The</i> , 2005, 365, 556-557.	13.7	42
588	Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. <i>Blood</i> , 1995, 86, 4553-8.	1.4	42
589	Direct podocyte damage in the single nephron leads to albuminuria in vivo. <i>Kidney International</i> , 1995, 47, 1078-1086.	5.2	41
590	Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. <i>Kidney International</i> , 2001, 59, 286-294.	5.2	41
591	Targeted Downregulation of Extracellular Nephron in Human IgA Nephropathy. <i>American Journal of Nephrology</i> , 2003, 23, 277-286.	3.1	41
592	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. <i>Molecular Immunology</i> , 2007, 44, 1704-1708.	2.2	41
593	Coagulation abnormalities in uremia. <i>Seminars in Nephrology</i> , 1985, 5, 82-90.	1.6	41
594	Prostacyclin and Thrombotic Microangiopathy. <i>Seminars in Thrombosis and Hemostasis</i> , 1980, 6, 391-394.	2.7	40

#	ARTICLE	IF	CITATIONS
595	Prevention of Renal Injury in Diabetic MWF Rats by Angiotensin II Antagonism. Nephron Experimental Nephrology, 1998, 6, 28-38.	2.2	40
596	Cigarette smoking and renal function impairment. American Journal of Kidney Diseases, 1999, 33, 807-810.	1.9	40
597	Aging and the kidney. Current Opinion in Nephrology and Hypertension, 2011, 20, 312-317.	2.0	40
598	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. Age, 2013, 35, 993-1005.	3.0	40
599	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2017, 92, 796-808.	5.2	40
600	Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS ONE, 2017, 12, e0178488.	2.5	40
601	Mesenchymal stromal cells for tolerance induction in organ transplantation. Human Immunology, 2018, 79, 304-313.	2.4	40
602	A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. EClinicalMedicine, 2021, 37, 100941.	7.1	40
603	REDUCTION OF FETAL VASCULAR PROSTACYCLIN ACTIVITY IN PRE-ECLAMPSIA. Lancet, The, 1980, 316, 310.	13.7	39
604	ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. American Journal of Physiology - Renal Physiology, 1999, 276, F457-F466.	2.7	39
605	Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy. Hypertension, 2010, 55, 1206-1209.	2.7	39
606	Angiotensin II Contributes to Diabetic Renal Dysfunction in Rodents and Humans via Notch1/Snail Pathway. American Journal of Pathology, 2013, 183, 119-130.	3.8	39
607	Physiology and Pathophysiology of Nitric Oxide in Chronic Renal Disease. Proceedings of the Association of American Physicians, 1999, 111, 602-610.	2.0	39
608	Protecting single-kidney allografts from long-term functional deterioration.. Journal of the American Society of Nephrology: JASN, 1998, 9, 1321-1332.	6.1	39
609	Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney International, 1991, 39, 647-652.	5.2	38
610	Edema of the Nephrotic Syndrome: The Role of the Atrial Peptide System. American Journal of Kidney Diseases, 1993, 22, 355-366.	1.9	38
611	Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. The Cochrane Library, 2008, , CD003233.	2.8	38
612	Developing Regulatory-compliant Electronic Case Report Forms for Clinical Trials: Experience with The Demand Trial. Journal of the American Medical Informatics Association: JAMIA, 2009, 16, 404-408.	4.4	38

#	ARTICLE	IF	CITATIONS
613	CD133+ renal stem cells always co-express CD24 in adult human kidney tissue. Stem Cell Research, 2014, 12, 828-829.	0.7	38
614	COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic. EBioMedicine, 2020, 61, 103069.	6.1	38
615	Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors. American Journal of Transplantation, 2006, 6, 2543-2547.	4.7	37
616	Computed Tomography Evaluation of Autosomal Dominant Polycystic Kidney Disease Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 754-760.	4.5	37
617	Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin. Journal of Immunology, 2008, 181, 1460-1469.	0.8	37
618	Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrology Dialysis Transplantation, 2009, 24, 1355-1358.	0.7	37
619	The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis and Tissue Repair, 2010, 3, 7.	3.4	37
620	Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1928-1938.	4.5	37
621	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology, the, 2013, 1, 19-27.	11.4	37
622	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Frontiers in Immunology, 2018, 9, 2329.	4.8	37
623	Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. Current Diabetes Reviews, 2011, 7, 190-200.	1.3	37
624	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides.. Journal of Experimental Medicine, 1994, 180, 1967-1972.	8.5	36
625	Renoprotective effects of renin-angiotensin-system inhibitors. Lancet, The, 2006, 367, 899-900.	13.7	36
626	Treatment With Pegylated Interferon and Ribavirin for Hepatitis C Virus-associated Severe Cryoglobulinemia in a Liver/Kidney Transplant Recipient. Journal of Clinical Gastroenterology, 2007, 41, 216-220.	2.2	36
627	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney International, 2012, 81, 903-918.	5.2	36
628	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. Nephron, 2016, 132, 59-69.	1.8	36
629	Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. Journal of the American Society of Nephrology: JASN, 2016, 27, 699-705.	6.1	36
630	Role of platelets in progressive glomerular diseases. Pediatric Nephrology, 1995, 9, 495-502.	1.7	35

#	ARTICLE	IF	CITATIONS
631	Cellular basis of long-term organ transplant acceptance: Pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. American Journal of Kidney Diseases, 1998, 31, 197-212.	1.9	35
632	The hemolytic uremic syndromes. Current Opinion in Critical Care, 2005, 11, 487-492.	3.2	35
633	Overview of randomised trials of ACE inhibitors. Lancet, The, 2006, 368, 555-556.	13.7	35
634	Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. British Journal of Dermatology, 2007, 157, 49-57.	1.5	35
635	The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics. American Journal of Nephrology, 2009, 30, 280-286.	3.1	35
636	Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice. Journal of Immunology, 2012, 189, 3661-3668.	0.8	35
637	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 785-794.	4.5	35
638	Platelet function in patients on maintenance hemodialysis: depressed or enhanced?. Clinical Nephrology, 1982, 17, 60-3.	0.7	35
639	The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney International, 1984, 25, 671-676.	5.2	34
640	Cyclosporine induces glomerulosclerosis: Three-dimensional definition of the lesions in a rat model of renal transplant. Kidney International, 1996, 49, 1283-1288.	5.2	34
641	Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. American Journal of Kidney Diseases, 1999, 33, 267-275.	1.9	34
642	Remission Achieved in Chronic Nephropathy by a Multidrug Approach Targeted at Urinary Protein Excretion. Nephron, 2001, 88, 254-259.	1.8	34
643	Adult nondiarrhea hemolytic uremic syndrome associated with shiga toxin escherichia coli O157:H7 bacteremia and urinary tract infection. American Journal of Kidney Diseases, 2003, 41, e4.1-e4.4.	1.9	34
644	ACE Inhibition versus Angiotensin Receptor Blockade: Which Is Better for Renal and Cardiovascular Protection?. Journal of the American Society of Nephrology: JASN, 2004, 15, 64S-70.	6.1	34
645	Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. American Journal of Kidney Diseases, 2013, 62, 984-992.	1.9	34
646	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 240-249.	6.1	34
647	Uremic bleeding: closing the circle after 30 years of controversies?. Blood, 1999, 94, 2569-74.	1.4	34
648	Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney International, 1990, 37, 934-942.	5.2	33

#	ARTICLE	IF	CITATIONS
649	Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. <i>Kidney International</i> , 1992, 41, 1081-1084.	5.2	33
650	Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 1997, 6, 489-495.	2.0	33
651	Peripheral donor leukocytes prolong survival of rat renal allografts. <i>Kidney International</i> , 1999, 56, 1101-1112.	5.2	33
652	Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1629-1634.	8.6	33
653	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	3.1	33
654	Novel Biomarkers for Renal Diseases? None for the Moment (but One). <i>Journal of Biomolecular Screening</i> , 2016, 21, 655-670.	2.6	33
655	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. <i>Pediatric Nephrology</i> , 2019, 34, 1311-1323.	1.7	33
656	At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. <i>Panminerva Medica</i> , 2021, 63, 51-61.	0.8	33
657	Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft.. <i>Journal of the American Society of Nephrology: JASN</i> , 1992, 2, 1398-1404.	6.1	33
658	Time course and localization of endothelin-1 gene expression in a model of renal disease progression. <i>American Journal of Pathology</i> , 1997, 151, 1241-7.	3.8	33
659	Following an Initial Decline, Glomerular Filtration Rate Stabilizes in Heart Transplant Patients on Chronic Cyclosporine. <i>American Journal of Kidney Diseases</i> , 1994, 24, 549-553.	1.9	32
660	Dendritic Cells Genetically Engineered with Adenoviral Vector Encoding dnIKK2 Induce the Formation of Potent CD4+ T-Regulatory Cells. <i>Transplantation</i> , 2005, 79, 1056-1061.	1.0	32
661	Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. <i>Seminars in Nephrology</i> , 2010, 30, 395-408.	1.6	32
662	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. <i>BMJ Open</i> , 2012, 2, bmjopen-2012-001357.	1.9	32
663	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1568-1574.	4.5	32
664	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. <i>American Journal of Transplantation</i> , 2017, 17, 2312-2325.	4.7	32
665	Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. <i>BMJ Case Reports</i> , 2020, 13, e232896.	0.5	32
666	Combined Treatment with Mycophenolate Mofetil and an Angiotensin II Receptor Antagonist Fully Protects from Chronic Rejection in a Rat Model of Renal Allograft. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1937-1946.	6.1	32

#	ARTICLE	IF	CITATIONS
667	Glomerular Hyperfiltration and Urinary Prostaglandins in Type 1 Diabetes Mellitus. <i>Diabetic Medicine</i> , 1989, 6, 219-223.	2.3	31
668	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. <i>American Journal of Medicine</i> , 1992, 92, S60-S63.	1.5	31
669	Post-transplant renal artery stenosis: The hemodynamic response to revascularization. <i>Kidney International</i> , 2001, 60, 309-318.	5.2	31
670	Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2666-2674.	6.1	31
671	Adeno-Associated Virus-Mediated CTLA4lg Gene Transfer Protects MHC-Mismatched Renal Allografts from Chronic Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1665-1672.	6.1	31
672	Clinical update: immunosuppression minimisation. <i>Lancet, The</i> , 2007, 369, 1676-1678.	13.7	31
673	Rare diseases: what's next?. <i>Lancet, The</i> , 2008, 371, 1978-1979.	13.7	31
674	Progression, Remission and Regression of Chronic Renal Diseases. <i>Nephron</i> , 2016, 134, 20-24.	1.8	31
675	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. <i>Frontiers in Immunology</i> , 2019, 10, 853.	4.8	31
676	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy. <i>Kidney International</i> , 2019, 96, 906-917.	5.2	31
677	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. <i>Blood Advances</i> , 2022, 6, 866-881.	5.2	31
678	Glomerular protein trafficking and progression of renal disease to terminal uremia. <i>Seminars in Nephrology</i> , 1996, 16, 151-9.	1.6	31
679	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. <i>Lancet, The</i> , 1992, 339, 1421.	13.7	30
680	Methylprednisolone normalizes superoxide anion production by polymorphs from patients with ANCA-positive vasculitides. <i>Kidney International</i> , 1993, 44, 215-220.	5.2	30
681	Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4lg. <i>Kidney International</i> , 1995, 47, 241-246.	5.2	30
682	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. <i>Kidney International</i> , 2003, 64, 2253-2261.	5.2	30
683	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 816, 99-105.	2.3	30
684	Translational Mini-Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. <i>Clinical and Experimental Immunology</i> , 2008, 151, 199-209.	2.6	30

#	ARTICLE	IF	CITATIONS
685	A German outbreak of haemolytic uraemic syndrome. <i>Lancet</i> , The, 2011, 378, 1057-1058.	13.7	30
686	Mesenchymal stromal cells to promote kidney transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 47-53.	1.6	30
687	B7a1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 999-1005.	6.1	30
688	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled<i>post hoc</i> analysis. <i>Transplant International</i> , 2017, 30, 1275-1283.	1.6	30
689	Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 299-308.	1.6	30
690	The thymic way to transplantation tolerance.. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 5, 1639-1646.	6.1	30
691	Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. <i>European Journal of Dermatology</i> , 2006, 16, 553-7.	0.6	30
692	Renal Biopsy in Patients With Acute Renal Failure and Prolonged Bleeding Time: A Preliminary Report. <i>American Journal of Kidney Diseases</i> , 1985, 6, 397-399.	1.9	29
693	ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. <i>Kidney International</i> , 1995, 47, 1319-1326.	5.2	29
694	Sympathetic Overactivity in Hypertensive Patients with Chronic Renal Disease. <i>New England Journal of Medicine</i> , 1999, 340, 1360-1361.	27.0	29
695	Shear Stress-Induced Cytoskeleton Rearrangement Mediates NF- κ B-Dependent Endothelial Expression of ICAM-1. <i>Microvascular Research</i> , 2000, 60, 182-188.	2.5	29
696	Generic cyclosporine formulations: more open questions than answers. <i>Transplant International</i> , 2005, 18, 371-378.	1.6	29
697	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. <i>Experimental Dermatology</i> , 2006, 15, 958-965.	2.9	29
698	Outcome of Renal Transplantation from Very Old Donors. <i>New England Journal of Medicine</i> , 2009, 360, 1464-1465.	27.0	29
699	Impact of thePPAR- γ 2Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. <i>Diabetes</i> , 2009, 58, 2920-2929.	0.6	29
700	Inherited thrombotic thrombocytopenic purpura. <i>Haematologica</i> , 2009, 94, 166-170.	3.5	29
701	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 1954-1956.	8.6	29
702	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 758-768.	1.8	29

#	ARTICLE	IF	CITATIONS
703	Early and late scanning electron microscopy findings in diabetic kidney disease. Scientific Reports, 2018, 8, 4909.	3.3	29
704	Superimposed Nephritis: A Separate Entity Among Glomerular Diseases?. American Journal of Kidney Diseases, 1986, 7, 205-212.	1.9	28
705	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. Kidney International, 1990, 38, 447-458.	5.2	28
706	Proteinuria in diabetic nephropathy: Treatment and evolution. Current Diabetes Reports, 2003, 3, 497-504.	4.2	28
707	Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. , 2004, , CD004293.		28
708	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney International, 2009, 75, 1050-1059.	5.2	28
709	PPAR-2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrology Dialysis Transplantation, 2011, 26, 4011-4016.	0.7	28
710	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2016, 68, 873-881.	1.9	28
711	Prevention programs for chronic kidney disease in low-income countries. Internal and Emergency Medicine, 2016, 11, 385-389.	2.0	28
712	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Current Opinion in Pharmacology, 2017, 33, 34-40.	3.5	28
713	Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney.. Journal of the American Society of Nephrology: JASN, 1990, 1, 799-807.	6.1	28
714	Measurement of glomerular filtration rate. Kidney International, Supplement, 1997, 63, S151-4.	0.1	28
715	Glomerular perm-selective function. Kidney International, 1994, 45, 398-402.	5.2	27
716	Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. American Journal of Kidney Diseases, 1996, 28, 23-31.	1.9	27
717	Renal Transplantation: Can We Reduce Calcineurin Inhibitor/Stop Steroids? Evidence Based on Protocol Biopsy Findings. Journal of the American Society of Nephrology: JASN, 2003, 14, 755-766.	6.1	27
718	Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells. Transplantation, 2005, 79, 1034-1039.	1.0	27
719	Immunophenotypic Analysis of Cellular Infiltrate of Renal Allograft Biopsies in Patients with Acute Rejection after Induction with Alemtuzumab (Campath-1H). Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 539-545.	4.5	27
720	Direct Reprogramming of Human Bone Marrow Stromal Cells into Functional Renal Cells Using Cell-free Extracts. Stem Cell Reports, 2015, 4, 685-698.	4.8	27

#	ARTICLE	IF	CITATIONS
721	Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery. EBioMedicine, 2018, 33, 253-268.	6.1	27
722	Endothelin Antagonists and Renal Protection. Journal of Cardiovascular Pharmacology, 2000, 35, S75-S78.	1.9	27
723	RENAL TRANSPLANTATION: SINGLE OR DUAL FOR DONORS AGING >60 YEARS?. Transplantation, 2000, 69, 2000-2001.	1.0	27
724	Bleeding in renal failure: a possible role of vascular prostacyclin (PGI ₂). Clinical Nephrology, 1979, 12, 127-31.	0.7	27
725	Catecholamine receptor binding in rat kidney: Effect of aging. Kidney International, 1988, 33, 1073-1077.	5.2	26
726	Endothelin and eicosanoid synthesis in cultured mesangial cells. Kidney International, 1990, 37, 927-933.	5.2	26
727	Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. Lancet, The, 1992, 339, 835-836.	13.7	26
728	Renal Prostacyclin Biosynthesis Is Reduced in Children With Hemolytic-Uremic Syndrome in the Context of Systemic Platelet Activation. American Journal of Kidney Diseases, 1992, 20, 144-149.	1.9	26
729	Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Kidney International, 1998, 54, 2146-2150.	5.2	26
730	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. Stem Cell Research and Therapy, 2018, 9, 220.	5.5	26
731	Accelerating the Depletion of Circulating Anti-Phospholipase A ₂ Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab. Nephron, 2020, 144, 30-35.	1.8	26
732	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet Journal of Rare Diseases, 2021, 16, 251.	2.7	26
733	New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. American Journal of Kidney Diseases, 1995, 26, 541-548.	1.9	25
734	17 β -Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. American Journal of Physiology - Renal Physiology, 2000, 279, F626-F635.	2.7	25
735	Hyperuricemia in Kidney Transplantation. , 2004, 147, 124-131.		25
736	Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor-Based Regimens. Hypertension, 2010, 56, 533-539.	2.7	25
737	Both Darbepoetin Alfa and Carbamylated Erythropoietin Prevent Kidney Graft Dysfunction Due to Ischemia/Reperfusion in Rats. Transplantation, 2011, 92, 271-279.	1.0	25
738	Erythropoietin enhances immunostimulatory properties of immature dendritic cells. Clinical and Experimental Immunology, 2011, 165, 202-210.	2.6	25

#	ARTICLE	IF	CITATIONS
739	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. <i>Diabetes</i> , 2013, 62, 3599-3609.	0.6	25
740	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. <i>American Journal of Kidney Diseases</i> , 2015, 66, 1067-1070.	1.9	25
741	BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. <i>American Journal of Kidney Diseases</i> , 2017, 70, 145-150.	1.9	25
742	Blood Pressure and Metabolic Effects of Acetyl-L-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. <i>Journal of the Endocrine Society</i> , 2018, 2, 420-436.	0.2	25
743	The role of B7-1 in proteinuria of glomerular origin. <i>Nature Reviews Nephrology</i> , 2018, 14, 589-596.	9.6	25
744	Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN Oby25 trial: A multi-country feasibility study. <i>PLoS Medicine</i> , 2021, 18, e1003408.	8.4	25
745	Albuminuria as early test for vascular disease. <i>Lancet</i> , The, 2005, 365, 556-557.	13.7	25
746	Thymic Microchimerism Correlates with the Outcome of Tolerance-Inducing Protocols for Solid Organ Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2815-2826.	6.1	25
747	Post-transplant Kaposi's sarcoma.. <i>Journal of the American Society of Nephrology: JASN</i> , 1997, 8, 130-137.	6.1	25
748	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0261113.	2.5	25
749	Prostacyclin (PGI2) and bleeding time in uremic patients. <i>Thrombosis Research</i> , 1977, 11, 919-920.	1.7	24
750	Inhibition of Human Platelet Aggregation by Parathyroid Hormone. <i>American Journal of Nephrology</i> , 1985, 5, 243-247.	3.1	24
751	Automatic Generation of Glomerular Capillary Topological Organization. <i>Microvascular Research</i> , 2001, 62, 346-354.	2.5	24
752	Complement factor H and hemolytic uremic syndrome. <i>International Immunopharmacology</i> , 2001, 1, 461-468.	3.8	24
753	Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. <i>Blood</i> , 2002, 100, 3839-3842.	1.4	24
754	Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 858-859.	0.7	24
755	Renal and Metabolic Effects of Insulin Lispro in Type 2 Diabetic Subjects With Overt Nephropathy. <i>Diabetes Care</i> , 2003, 26, 502-509.	8.6	24
756	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. <i>Kidney International</i> , 2004, 65, 1084-1090.	5.2	24

#	ARTICLE	IF	CITATIONS
757	Independent clinical research in Europe. Lancet, The, 2004, 364, 1723-1726.	13.7	24
758	Subcutaneous xenotransplantation of bovine pancreatic islets. Biomaterials, 2005, 26, 5640-5647.	11.4	24
759	Pathophysiology of disease progression in proteinuric nephropathies. Kidney International, 2005, 67, S79-S82.	5.2	24
760	Dual Blockade of the Renin-Angiotensin System. Journal of the American Society of Nephrology: JASN, 2005, 16, S34-S38.	6.1	24
761	Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrology Dialysis Transplantation, 2005, 20, 1741-1744.	0.7	24
762	Decision time for pancreatic islet-cell transplantation. Lancet, The, 2008, 371, 883-884.	13.7	24
763	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. EBioMedicine, 2015, 2, 456-466.	6.1	24
764	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes and Endocrinology, the, 2018, 6, 27-40.	11.4	24
765	Effects of angiotensin-converting enzyme inhibition on glomerular capillary wall ultrastructure in MWF/Ztm rats.. Journal of the American Society of Nephrology: JASN, 1994, 5, 1378-1384.	6.1	24
766	Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney International, Supplement, 1997, 63, S54-7.	0.1	24
767	Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplantation Reviews, 1991, 5, 63-80.	2.9	23
768	Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Current Opinion in Nephrology and Hypertension, 2001, 10, 1-6.	2.0	23
769	Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney International, 2002, 62, 1010-1019.	5.2	23
770	Cyclosporine Prolongs Delayed Graft Function in Kidney Transplantation: Are Rabbit Anti-Human Thymocyte Globulins the Answer?. Nephron Clinical Practice, 2005, 101, c65-c71.	2.3	23
771	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Current Opinion in Organ Transplantation, 2010, 15, 731-737.	1.6	23
772	Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1400-1402.	6.1	23
773	Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Annals of the Rheumatic Diseases, 2014, 73, 475-476.	0.9	23
774	Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. Current Opinion in Organ Transplantation, 2015, 20, 79-85.	1.6	23

#	ARTICLE	IF	CITATIONS
775	Nephrology researchâ€”the past, present and future. <i>Nature Reviews Nephrology</i> , 2015, 11, 677-687.	9.6	23
776	Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. <i>Microorganisms</i> , 2019, 7, 15.	3.6	23
777	Unrecognized Pattern of von Willebrand Factor Abnormalities in Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1234-1241.	6.1	23
778	Endothelin: a mediator of renal disease progression. <i>Journal of Nephrology</i> , 1997, 10, 179-83.	2.0	23
779	Skin fibroblasts from a patient with Glanzmann's Thrombasthenia do not induce fibrin clot retraction. <i>Thrombosis Research</i> , 1977, 10, 173-174.	1.7	22
780	RENAL BIOPSY IN PATIENTS WITH ACUTE RENAL FAILURE AND PROLONGED BLEEDING TIME. <i>Lancet, The</i> , 1984, 324, 978-979.	13.7	22
781	Angiotensin-Converting Enzyme Inhibition Ameliorates the Defect in Glomerular Size Selectivity in Hyponatremic Hypertensive Syndrome. <i>American Journal of Kidney Diseases</i> , 1989, 14, 170-177.	1.9	22
782	CO-PARTICIPATION OF THROMBOXANE A2 AND LEUKOTRIENE C4 AND D4 IN MEDIATING CYCLOSPORINE-INDUCED ACUTE RENAL FAILURE. <i>Transplantation</i> , 1991, 52, 873-878.	1.0	22
783	Glucose-induced changes in renal haemodynamics in proteinuric Type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicylic acid infusion. <i>Diabetologia</i> , 1993, 36, 622-627.	6.3	22
784	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. <i>Kidney International</i> , 1993, 43, 426-429.	5.2	22
785	Î±1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. <i>Lancet, The</i> , 1995, 345, 224-225.	13.7	22
786	Acceleration of Recovery in Acute Renal Failure: From Cellular Mechanisms of Tubular Repair to Innovative Targeted Therapies. <i>Renal Failure</i> , 1996, 18, 377-388.	2.1	22
787	Routine renin-angiotensin system blockade in renal transplantation?. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 1-10.	2.0	22
788	Nitric Oxide Synthetic Capacity in Relation to Dialysate Temperature. <i>Blood Purification</i> , 2004, 22, 203-209.	1.8	22
789	Albumin concentration in the Bowman's capsule: Multiphoton microscopy vs micropuncture technique. <i>Kidney International</i> , 2007, 72, 1410-1411.	5.2	22
790	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. <i>Journal of Hypertension</i> , 2007, 25, 871-876.	0.5	22
791	Sirolimus to replace calcineurin inhibitors? Too early yet. <i>Lancet, The</i> , 2009, 373, 1235-1236.	13.7	22
792	Systems biology to battle vascular disease. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1019-1022.	0.7	22

#	ARTICLE	IF	CITATIONS
793	A previously unrecognized role of C3a in proteinuric progressive nephropathy. Scientific Reports, 2016, 6, 28445.	3.3	22
794	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	1.7	22
795	RECOVERY OF BLOOD MONONUCLEAR CELL CALCINEURIN ACTIVITY SEGREGATES TWO POPULATIONS OF RENAL TRANSPLANT PATIENTS WITH DIFFERENT SENSITIVITIES TO CYCLOSPORINE INHIBITION. Transplantation, 1996, 61, 1526-1531.	1.0	22
796	A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity.. Journal of the American Society of Nephrology: JASN, 1996, 7, 786-791.	6.1	22
797	Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Experimental Nephrology, 1996, 4, 19-25.	0.4	22
798	Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia. Clinical Transplantation, 1996, 10, 550-5.	1.6	22
799	Glomerular response to hyperglycemia in human diabetic nephropathy. American Journal of Physiology - Renal Physiology, 1990, 259, F545-F552.	2.7	21
800	Defective Platelet Aggregation in Response to Platelet-Activating Factor in Uremia Associated With Low Platelet Thromboxane A2 Generation. American Journal of Kidney Diseases, 1992, 19, 318-325.	1.9	21
801	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney International, 1992, 42, 981-990.	5.2	21
802	Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney International, 1993, 44, 436-439.	5.2	21
803	Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. Kidney International, 2003, 63, 1948-1950.	5.2	21
804	DnIKK2-Transfected Dendritic Cells Induce a Novel Population of Inducible Nitric Oxide Synthase???Expressing CD4+CD25??? Cells with Tolerogenic Properties. Transplantation, 2007, 83, 474-484.	1.0	21
805	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports, 2007, 9, 430-436.	3.5	21
806	Enzyme Replacement Therapy and Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 371-378.	4.5	21
807	Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. Transplant International, 2011, 24, 829-838.	1.6	21
808	Old Donors for Kidney Transplantation: How Old?. Gerontology, 2011, 57, 513-520.	2.8	21
809	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Tj ETQq1 1 0.784314 rgBT /Ov Diseases, 2013, 61, 238-246.	1.9	21
810	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. Nephrology Dialysis Transplantation, 2013, 28, 2841-2850.	0.7	21

#	ARTICLE	IF	CITATIONS
811	Acute kidney injury in low-income and middle-income countries: no longer a death sentence. The Lancet Global Health, 2016, 4, e216-e217.	6.3	21
812	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. Nephron, 2018, 140, 1-8.	1.8	21
813	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. JCI Insight, 2019, 4, .	5.0	21
814	Thymus-mediated immune tolerance to renal allograft is donor but not tissue specific.. Journal of the American Society of Nephrology: JASN, 1991, 2, 1063-1071.	6.1	21
815	Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the <scp>VEGF&A</scp>/caveolin&A</scp>PV</scp>&A</scp> signaling pathway. Journal of Pathology, 2022, 256, 468-479.	4.5	21
816	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-8.	3.4	21
817	Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. Kidney International, 1992, 41, 813-821.	5.2	20
818	Nitric Oxide<i>L</i>-Arginine in Uremia. Mineral and Electrolyte Metabolism, 1999, 25, 384-390.	1.1	20
819	Lessons from the Di Bella affair. Lancet, The, 1999, 353, 1289-1290.	13.7	20
820	Modulating the profit motive to meet needs of the less-developed world. Lancet, The, 2001, 358, 1638-1641.	13.7	20
821	Dual Renin-Angiotensin System Blockade for Nephroprotection: Still under Scrutiny. Nephron, 2015, 129, 39-41.	1.8	20
822	Acute kidney injury: more awareness needed, globally. Lancet, The, 2015, 386, 1425-1427.	13.7	20
823	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology, 2017, 37, 447-463.	1.6	20
824	The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. American Journal of Pathology, 2017, 187, 2441-2450.	3.8	20
825	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. Stem Cells Translational Medicine, 2020, 9, 427-432.	3.3	20
826	Third-party bone marrow&A</i>-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. American Journal of Transplantation, 2021, 21, 2795-2809.	4.7	20
827	Xenogeneic Serum Promotes Leukocyte-Endothelium Interaction under Flow through Two Temporally Distinct Pathways. Journal of the American Society of Nephrology: JASN, 1999, 10, 2197-2207.	6.1	20
828	Platelet-activating factor mediates angiotensin II-induced proteinuria in isolated perfused rat kidney.. Journal of the American Society of Nephrology: JASN, 1997, 8, 1391-1398.	6.1	20

#	ARTICLE	IF	CITATIONS
829	Pathophysiologic implications of proteinuria in a rat model of progressive glomerular injury. Laboratory Investigation, 1992, 67, 572-9.	3.7	20
830	Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. Laboratory Investigation, 1991, 64, 16-20.	3.7	20
831	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-64.	3.4	20
832	Sequence of Glomerular Changes in Experimental Endotoxemia: A Possible Model of Hemolytic Uremic Syndrome. Nephron, 1989, 53, 330-337.	1.8	19
833	Slowing the Progression of Diabetic Nephropathy. New England Journal of Medicine, 1993, 329, 1496-1497.	27.0	19
834	Italy. Lancet, The, 1996, 348, 167-175.	13.7	19
835	Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation. American Journal of Transplantation, 2005, 5, 1175-1176.	4.7	19
836	Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. Nature Clinical Practice Nephrology, 2005, 1, 2-3.	2.0	19
837	Kidney Failure Stabilizes after a Two-Decade Increase: Impact on Global (Renal and Cardiovascular) Health. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 146-150.	4.5	19
838	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenetics and Genomics, 2009, 19, 695-703.	1.5	19
839	Which antihypertensive drugs are the most nephroprotective and why?. Expert Opinion on Pharmacotherapy, 2010, 11, 2651-2663.	1.8	19
840	Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. American Journal of Pathology, 2011, 179, 619-627.	3.8	19
841	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. Pediatric Nephrology, 2012, 27, 1989-1993.	1.7	19
842	Mortality landscape in the Global Burden of Diseases, Injuries and Risk Factors Study. European Journal of Internal Medicine, 2014, 25, 1-5.	2.2	19
843	Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?. European Journal of Heart Failure, 2015, 17, 468-471.	7.1	19
844	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism, 2017, 19, 749-753.	4.4	19
845	Prolonged bleeding time and increased vascular prostacyclin in rats with chronic renal failure: effects of conjugated estrogens. Translational Research, 1988, 112, 380-6.	2.3	19
846	Hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infection in acquired immunodeficiency syndrome [letter]. Blood, 1990, 75, 2465-2465.	1.4	18

#	ARTICLE	IF	CITATIONS
847	Thrombotic microangiopathies. Critical Reviews in Oncology/Hematology, 1991, 11, 243-265.	4.4	18
848	The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. Current Opinion in Nephrology and Hypertension, 1997, 6, 141-145.	2.0	18
849	Endothelin receptor antagonists: which are the therapeutic perspectives in renal diseases?. Nephrology Dialysis Transplantation, 1998, 13, 5-7.	0.7	18
850	Renoprotective Therapy in Patients With Nondiabetic Nephropathies. Drugs, 2001, 61, 733-745.	10.9	18
851	Nonimmunosuppressive therapy of membranous nephropathy. Seminars in Nephrology, 2003, 23, 333-339.	1.6	18
852	The future of renoprotection. Kidney International, 2005, 68, S95-S101.	5.2	18
853	Latest treatment strategies for membranous nephropathy. Expert Opinion on Pharmacotherapy, 2007, 8, 3159-3171.	1.8	18
854	Primer: strategies for identifying genes involved in renal disease. Nature Clinical Practice Nephrology, 2008, 4, 265-276.	2.0	18
855	Aldosterone and progression of kidney disease. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 133-143.	2.1	18
856	Rituximab for membranous nephropathy and immune disease: less might be enough. Nature Clinical Practice Nephrology, 2009, 5, 76-77.	2.0	18
857	Renal Bioengineering with Scaffolds Generated from Rat and Pig Kidneys. Nephron Experimental Nephrology, 2014, 126, 113-118.	2.2	18
858	Eliminating Treatable Deaths Due to Acute Kidney Injury in Resource-Poor Settings. Seminars in Dialysis, 2015, 28, 193-197.	1.3	18
859	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	1.9	18
860	Effect of dietary proteins and lipids in patients with membranous nephropathy and nephrotic syndrome. Clinical Nephrology, 1991, 35, 237-42.	0.7	18
861	Enhanced glomerular thromboxane A2 mediates some pathophysiologic effect of platelet-activating factor in rabbit nephrotoxic nephritis: evidence from biochemical measurements and inhibitor trials. Translational Research, 1989, 113, 549-60.	2.3	18
862	Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation, 1994, 58, 125-32.	1.0	18
863	Passive Heymann nephritis: evidence that angiotensin-converting enzyme inhibition reduces proteinuria and retards renal structural injury. Experimental Nephrology, 1996, 4, 213-21.	0.4	18
864	Human renal cortex generates prostacyclin-like activity. Thrombosis Research, 1978, 12, 363-366.	1.7	17

#	ARTICLE	IF	CITATIONS
865	In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. <i>Kidney International</i> , 1983, 23, 506-513.	5.2	17
866	Increased urinary excretion of platelet activating factor in mice with lupus nephritis. <i>Life Sciences</i> , 1991, 48, 1429-1437.	4.3	17
867	Epidemiology of the Hemolytic Uremic Syndrome. <i>New England Journal of Medicine</i> , 1991, 324, 1065-1066.	27.0	17
868	Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?. <i>Kidney International</i> , 2005, 68, S21-S24.	5.2	17
869	Non-immune interventions to protect kidney allografts in the long term. <i>Kidney International</i> , 2010, 78, S71-S75.	5.2	17
870	Targeting the Renin Angiotensin System in Dialysis Patients. <i>Seminars in Dialysis</i> , 2011, 24, 290-297.	1.3	17
871	Nephrology in developing countries: the ISN's story. <i>Lancet, The</i> , 2014, 383, 1271-1272.	13.7	17
872	Renal Primordia Activate Kidney Regenerative Events in a Rat Model of Progressive Renal Disease. <i>PLoS ONE</i> , 2015, 10, e0120235.	2.5	17
873	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	1.9	17
874	Platelet-activating factor receptor blocking reduces proteinuria and improves survival in lupus autoimmune mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1991, 258, 601-6.	2.5	17
875	Recurrent abortion with lupus anticoagulant, and pre-eclampsia: a common final pathway for two different diseases? Case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1986, 93, 194-196.	2.3	16
876	Role of Platelet-Activating Factor in Renal Immune Injury and Proteinuria. <i>American Journal of Nephrology</i> , 1990, 10, 98-104.	3.1	16
877	Angiotensin II receptor antagonists and treatment of hypertension and renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 571-578.	2.0	16
878	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. , 2005, 15, 71-76.		16
879	Thrice-Weekly In-Center Nocturnal Hemodialysis: An Effective Strategy to Optimize Chronic Dialysis Therapy. <i>International Journal of Artificial Organs</i> , 2009, 32, 12-19.	1.4	16
880	Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. <i>Journal of Hypertension</i> , 2010, 28, 186-193.	0.5	16
881	Successes and Disappointments with Clinical Islet Transplantation. <i>Advances in Experimental Medicine and Biology</i> , 2010, 654, 749-769.	1.6	16
882	Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial. <i>Journal of Ophthalmology</i> , 2010, 2010, 1-9.	1.3	16

#	ARTICLE	IF	CITATIONS
883	Non-muscle myosins and the podocyte. CKJ: Clinical Kidney Journal, 2012, 5, 94-101.	2.9	16
884	Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II. PLoS ONE, 2015, 10, e0127172.	2.5	16
885	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. Journal of the American Society of Nephrology: JASN, 2020, 31, 517-531.	6.1	16
886	Myasthenia Gravis, Thrombocytopenia and HLA Antigens. Annals of Internal Medicine, 1977, 87, 250.	3.9	15
887	PROSTACYCLIN DEFICIENCY IN THROMBOTIC MICROANGIOPATHY. Lancet, The, 1981, 318, 1422-1423.	13.7	15
888	Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes.. Circulation Research, 1990, 66, 1453-1460.	4.5	15
889	Low-Protein Diet and Glomerular Size-Selective Function in Membranous Glomerulopathy. American Journal of Kidney Diseases, 1991, 17, 317-322.	1.9	15
890	Heparin-induced thrombocytopenia-background and implications for haemodialysis. Nephrology Dialysis Transplantation, 1996, 11, 2120-2122.	0.7	15
891	Acquired transplant tolerance. International Journal of Clinical and Laboratory Research, 1997, 27, 165-177.	1.0	15
892	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: Not simply overestimation. Clinica Chimica Acta, 2005, 355, 153-164.	1.1	15
893	Proteinuria and its consequences in renal disease. Acta Paediatrica, International Journal of Paediatrics, 2003, 92, 9-13.	1.5	15
894	What not to learn from a meta-analysis. Nature Reviews Nephrology, 2009, 5, 186-188.	9.6	15
895	THE DIABETIC CKD PATIENT—A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care, 2010, 36, 34-46.	1.2	15
896	Novel effective drugs for diabetic kidney disease? or not?. Expert Opinion on Emerging Drugs, 2014, 19, 571-601.	2.4	15
897	Management of chronic kidney disease and its risk factors in eastern Nepal. The Lancet Global Health, 2014, 2, e506-e507.	6.3	15
898	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	1.9	15
899	The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. Pharmacoeconomics - Open, 2018, 2, 459-467.	1.8	15
900	Toward longitudinal studies of hemodynamically induced vessel wall remodeling. International Journal of Artificial Organs, 2018, 41, 714-722.	1.4	15

#	ARTICLE	IF	CITATIONS
901	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. Scientific Reports, 2019, 9, 2225.	3.3	15
902	Bergamo and Covid-19: How the Dark Can Turn to Light. Frontiers in Medicine, 2021, 8, 609440.	2.6	15
903	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American Journal of Nephrology, 2021, 52, 827-836.	3.1	15
904	Cyclooxygenase products and atrial natriuretic peptide modulate renal response to endothelin. Journal of Pharmacology and Experimental Therapeutics, 1990, 252, 1213-20.	2.5	15
905	Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat. Journal of Pharmacology and Experimental Therapeutics, 1989, 248, 334-41.	2.5	15
906	A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2). Frontiers in Medicine, 2022, 9, 785785.	2.6	15
907	EVIDENCE OF THE CENTRAL ROLE OF THE THYMUS IN THE INDUCTION OF DONOR-SPECIFIC UNRESPON-SIVENESS TO A RENAL ALLOGRAFT. Transplantation, 1992, 54, 943-944.	1.0	14
908	Nonviral and Viral Gene Transfer to the Kidney in the Context of Transplantation. Nephron, 2000, 85, 307-316.	1.8	14
909	A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. American Journal of Kidney Diseases, 2000, 36, 695-702.	1.9	14
910	Losartan in diabetic nephropathy. Expert Review of Cardiovascular Therapy, 2004, 2, 473-483.	1.5	14
911	Cyclosporine Formulation and Kaposi's Sarcoma after Renal Transplantation. Transplantation, 2005, 80, 743-748.	1.0	14
912	Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. Xenotransplantation, 2005, 12, 110-120.	2.8	14
913	Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation. American Journal of Transplantation, 2009, 9, 2856-2857.	4.7	14
914	Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?. Pharmaceuticals, 2010, 3, 1-9.	3.8	14
915	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 1177-1190.	4.4	14
916	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. Transplantation, 2019, 103, 1121-1130.	1.0	14
917	Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?. Nephrology Dialysis Transplantation, 2021, 37, ii55-ii62.	0.7	14
918	Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation. Frontiers in Immunology, 2020, 11, 618243.	4.8	14

#	ARTICLE	IF	CITATIONS
919	Peripheral donor leukocytes prolong survival of rat renal allografts. <i>Kidney International</i> , 1999, 56, 1101.	5.2	14
920	Blocking cell microtubule assembly inhibits the alloimmune response in vitro and prolongs renal allograft survival by inhibition of Th1 and sparing of Th2 cell function in vivo.. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 5, 1418-1425.	6.1	14
921	The renal toxicity of sustained glomerular protein traffic. <i>Laboratory Investigation</i> , 1995, 73, 461-8.	3.7	14
922	ABNORMAL TISSUE REPAIR IN GLANZMANN'S THROMBASTHENIA. <i>Lancet, The</i> , 1977, 309, 374-375.	13.7	13
923	High-performance liquid chromatographic determination of iothalamic acid in human plasma and urine. <i>Biomedical Applications</i> , 1991, 570, 435-440.	1.7	13
924	Renal Handling of Sodium in the Nephrotic Syndrome. <i>American Journal of Nephrology</i> , 1993, 13, 413-421.	3.1	13
925	Role of Endothelin in the Development of Glomerulosclerosis. <i>Kidney and Blood Pressure Research</i> , 1996, 19, 182-183.	2.0	13
926	Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. <i>Kidney International</i> , 2003, 64, 857-863.	5.2	13
927	Fighting Renal Diseases in Poor Countries: Building a Global Fund with the Help of the Pharmaceutical Industry. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 704-707.	6.1	13
928	Review: Potential protective effects of telmisartan on renal function deterioration. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006, 7, 185-191.	1.7	13
929	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. <i>Gene Therapy</i> , 2009, 16, 1373-1379.	4.5	13
930	Do mTOR inhibitors still have a future in ADPKD?. <i>Nature Reviews Nephrology</i> , 2010, 6, 696-698.	9.6	13
931	Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 300, F1291-F1300.	2.7	13
932	Thrombotic Microangiopathies: From Animal Models to Human Disease and Cure. <i>Contributions To Nephrology</i> , 2011, 169, 337-350.	1.1	13
933	Clinical use of computational modeling for surgical planning of arteriovenous fistula for hemodialysis. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 26.	3.0	13
934	Mesenchymal stromal cells in kidney transplantation. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 40-46.	2.0	13
935	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. <i>International Journal of Cardiology</i> , 2019, 275, 145-151.	1.7	13
936	Preliminary results of intrathymic injection of donor cells to prevent acute rejection in human heart transplantation.. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 6, 1291-1294.	6.1	13

#	ARTICLE	IF	CITATIONS
937	Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial. <i>EClinicalMedicine</i> , 2022, 43, 101227.	7.1	13
938	Age-related nephropathy and proteinuria in rats with intact kidneys exposed to diets with different protein content. <i>Laboratory Investigation</i> , 1989, 60, 196-204.	3.7	13
939	Effect of aspirin and sulindac in rabbit nephrotoxic nephritis. <i>Translational Research</i> , 1986, 107, 261-8.	2.3	13
940	The renin-angiotensin system in progression, remission and regression of chronic nephropathies. <i>Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension</i> , 2002, 20, S45-53.	0.1	13
941	Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. <i>American Journal of Physiology - Renal Physiology</i> , 1987, 253, F318-F327.	2.7	12
942	Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NF- κ B. <i>Xenotransplantation</i> , 1998, 5, 57-60.	2.8	12
943	A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 58-60.	0.7	12
944	Repairing renal lesions: Will VEGF be the builder?. <i>Kidney International</i> , 2000, 58, 2594-2595.	5.2	12
945	Thrombotic microangiopathy. <i>European Journal of Internal Medicine</i> , 2000, 11, 135-139.	2.2	12
946	ACE inhibitors and AT1 receptor antagonists: Is two better than one?. <i>Kidney International</i> , 2002, 61, 1545-1547.	5.2	12
947	Favorable Effect of Cotransfection with TGF- β 2 and CTLA4Ig of the Donor Kidney on Allograft Survival. <i>American Journal of Nephrology</i> , 2004, 24, 275-283.	3.1	12
948	The potential of endothelin antagonism as a therapeutic approach. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1419-1435.	4.1	12
949	Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. <i>American Journal of Nephrology</i> , 2007, 27, 630-638.	3.1	12
950	Increased angiotensin-receptor blocking is not the first option. <i>Nature Reviews Nephrology</i> , 2009, 5, 367-368.	9.6	12
951	Dealing with Renin-Angiotensin Inhibitors, Don't Mind Serum Creatinine. <i>American Journal of Nephrology</i> , 2012, 36, 427-429.	3.1	12
952	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2002-2012.	4.5	12
953	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. <i>Journal of Biological Chemistry</i> , 2016, 291, 8214-8230a.	3.4	12
954	Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?. <i>American Journal of Kidney Diseases</i> , 2017, 70, 754-757.	1.9	12

#	ARTICLE	IF	CITATIONS
955	Achieving remission of proteinuria in childhood CKD. <i>Pediatric Nephrology</i> , 2017, 32, 321-330.	1.7	12
956	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 283-290.	0.7	12
957	Renal metabolism and urinary excretion of platelet-activating factor in the rat.. <i>Journal of Biological Chemistry</i> , 1990, 265, 19414-19419.	3.4	12
958	CTLA4Ig ALONE OR IN COMBINATION WITH LOW-DOSE CYCLOSPORINE FAILS TO REVERSE ACUTE REJECTION OF RENAL ALLOGRAFT IN THE RAT. <i>Transplantation</i> , 1996, 61, 1320-1322.	1.0	12
959	Immunosuppressive therapy abrogates unresponsiveness to renal allograft induced by thymic recognition of donor antigens.. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 5, 1618-1623.	6.1	12
960	COVID-19 pandemic and total mortality in the first six months of 2020 in Italy. <i>Medicina Del Lavoro</i> , 2020, 111, 351-353.	0.4	12
961	Disaster medicine and response: Optimizing life-saving potential. <i>American Journal of Disaster Medicine</i> , 2018, 13, 253-264.	0.3	12
962	Selective inhibition of platelet thromboxane generation with low-dose aspirin does not protect rats with reduced renal mass from the development of progressive disease. <i>American Journal of Pathology</i> , 1989, 134, 1027-38.	3.8	12
963	Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. <i>Experimental Nephrology</i> , 1994, 2, 220-8.	0.4	12
964	The hemolytic uremic syndrome. <i>Kidney International, Supplement</i> , 1998, 66, S54-7.	0.1	12
965	Heparin for Hemodialysis: Practical Guidelines for Administration and Monitoring. <i>International Journal of Artificial Organs</i> , 1984, 7, 269-274.	1.4	11
966	Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome. <i>Lancet, The</i> , 1990, 336, 533-534.	13.7	11
967	Supernatant of endothelial cells exposed to laminar flow inhibits mesangial cell proliferation. <i>American Journal of Physiology - Cell Physiology</i> , 1993, 264, C1080-C1083.	4.6	11
968	The renoprotective potential of endothelin receptor antagonists. <i>Expert Opinion on Therapeutic Patents</i> , 1997, 7, 139-149.	5.0	11
969	Renoprotective effect of ACE inhibitors: Dissecting the molecular clues and expanding the blood pressure goal. <i>American Journal of Kidney Diseases</i> , 1999, 34, 951-954.	1.9	11
970	Optimization of cyclosporine therapy in the neoral era: abbreviated AUC, single blood sampling?. <i>Transplantation Proceedings</i> , 2001, 33, 3117-3119.	0.6	11
971	Novel mechanism(s) implicated in tubular albumin reabsorption and handling. <i>American Journal of Kidney Diseases</i> , 2001, 38, 196-200.	1.9	11
972	Investigational drugs for diabetic nephropathy. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1487-1500.	4.1	11

#	ARTICLE	IF	CITATIONS
973	Prevalence of Hypertension and Diabetes and Coexistence of Chronic Kidney Disease and Cardiovascular Risk in the Population of the Republic of Moldova. International Journal of Hypertension, 2012, 2012, 1-8.	1.3	11
974	Advances in the Pathology of Glomerular Diseases. Contributions To Nephrology, 2013, 181, 12-21.	1.1	11
975	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.7	11
976	Acute Kidney Injury in Poor Countries Should No Longer Be a Death Sentence: The ISN "0 by 25" Project. Annals of Nutrition and Metabolism, 2015, 66, 42-44.	1.9	11
977	Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. Pharmacological Research, 2016, 108, 16-22.	7.1	11
978	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ Global Health, 2017, 2, e000453.	4.7	11
979	Therapeutic Plasma Exchange in Neonates and Infants: Successful Use of a Miniaturized Machine. Blood Purification, 2017, 44, 100-105.	1.8	11
980	Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. PLoS ONE, 2018, 13, e0202417.	2.5	11
981	Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?. Kidney International, 2019, 96, 13-15.	5.2	11
982	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in Genetics, 2019, 10, 681.	2.3	11
983	CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Genetics, 2021, 12, 670727.	2.3	11
984	Colchicine allows prolonged survival of highly reactive renal allograft in the rat.. Journal of the American Society of Nephrology: JASN, 1993, 4, 1294-1299.	6.1	11
985	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23.	0.7	11
986	17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. Journal of Pharmacology and Experimental Therapeutics, 1990, 252, 344-8.	2.5	11
987	Bleeding disorders in uremia: pathophysiology and treatment. Advances in Nephrology From the Necker Hospital, 1989, 18, 171-86.	0.2	11
988	Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins?. Clinical Nephrology, 1986, 25 Suppl 1, S83-8.	0.7	11
989	Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and discloses predisposition in families. The Italian Registry of Familial and Recurrent HUS/TTP. Blood, 1999, 94, 610-20.	1.4	11
990	Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clinical Chemistry, 2001, 47, 1679-87.	3.2	11

#	ARTICLE	IF	CITATIONS
991	The Lupus Anticoagulant. <i>Experimental Biology and Medicine</i> , 1984, 176, 337-341.	2.4	10
992	What Is the Basis for the Use of Steroids in the Treatment of Idiopathic Membranous Nephropathy?. <i>Nephron</i> , 1987, 45, 1-6.	1.8	10
993	Studies by conventional and isoelectric focusing on albumin microheterogeneity under normal conditions and in experimental nephrosis. <i>Electrophoresis</i> , 1987, 8, 215-220.	2.4	10
994	Influence of Antacid Administrations on Aspirin Absorption in Patients With Chronic Renal Failure on Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 1988, 11, 338-342.	1.9	10
995	Glomerulonephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 1993, 2, 465-474.	2.0	10
996	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. <i>Kidney International</i> , 2000, 58, 2093-2101.	5.2	10
997	Xenotransplantation in the 21st Century. <i>Blood Purification</i> , 2002, 20, 45-54.	1.8	10
998	Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. <i>Kidney International</i> , 2002, 61, S115-S119.	5.2	10
999	Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. <i>Kidney International</i> , 2003, 63, 1924-1933.	5.2	10
1000	The KIDSTEM European Research Training Network. <i>Organogenesis</i> , 2007, 3, 2-5.	1.2	10
1001	Inhibition of TGF- β 2 expression: A novel role for thiazolidinediones to implement renoprotection in diabetes. <i>Kidney International</i> , 2007, 72, 1419-1421.	5.2	10
1002	Pharmacokinetic/Pharmacodynamic Drug Interaction Between Rosiglitazone and Mycophenolate Mofetil in Kidney Transplantation: A Case Report. <i>Transplantation</i> , 2008, 85, 921-922.	1.0	10
1003	The ERA-EDTA Working Group on inherited kidney disorders. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 67-69.	0.7	10
1004	A preclinical overview of emerging therapeutic targets for glomerular diseases. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 593-606.	3.4	10
1005	Role of ultrastructural determinants of glomerular permeability in ultrafiltration function loss. <i>JCI Insight</i> , 2020, 5, .	5.0	10
1006	Interleukin-1 regulates cytokine gene expression in human mesangial cells through the interleukin-1 receptor type 1. <i>Journal of the American Society of Nephrology: JASN</i> , 1992, 2, 1709-1715.	6.1	10
1007	Managing hypertension in diabetic patients-focus on trandolapril/verapamil combination. <i>Vascular Health and Risk Management</i> , 2007, 3, 453-65.	2.3	10
1008	Renal metabolism and urinary excretion of platelet-activating factor in the rat. <i>Journal of Biological Chemistry</i> , 1990, 265, 19414-9.	3.4	10

#	ARTICLE	IF	CITATIONS
1009	Transplant tolerance: progress and challenges. Journal of Nephrology, 2010, 23, 263-70.	2.0	10
1010	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). Diabetes Research and Clinical Practice, 2022, 185, 109804.	2.8	10
1011	Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. Scientific Reports, 2021, 11, 23580.	3.3	10
1012	Excess total mortality during the Covid-19 pandemic in Italy: updated estimates indicate persistent excess in recent months.. Medicina Del Lavoro, 2022, 113, e2022021.	0.4	10
1013	Factor VIII-related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times.. BMJ: British Medical Journal, 1978, 1, 70-72.	2.3	9
1014	Prevalence and Significance of Hypertension in Systemic Lupus Erythematosus. American Journal of Kidney Diseases, 1993, 21, 58-60.	1.9	9
1015	Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. American Journal of Physiology - Renal Physiology, 1994, 267, F1034-F1044.	2.7	9
1016	Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking?. Nephrology Dialysis Transplantation, 1998, 13, 2734-2738.	0.7	9
1017	Effect of Cigarette Smoking on Renal Function and Vascular Endothelium. , 2000, 130, 45-52.		9
1018	One or two marginal organs for kidney transplantation?. Transplantation Proceedings, 2002, 34, 3091-3096.	0.6	9
1019	Emerging drugs for diabetic nephropathy. Expert Opinion on Emerging Drugs, 2005, 10, 747-771.	2.4	9
1020	Treating the kidney to cure the heart. Kidney International, 2008, 74, S2-S3.	5.2	9
1021	Time to rethink immunosuppression by mTOR inhibitors?. Nature Reviews Nephrology, 2009, 5, 611-612.	9.6	9
1022	Embryonic Stem Cells, Derived Either after In Vitro Fertilization or Nuclear Transfer, Prolong Survival of Semiallogeneic Heart Transplants. Journal of Immunology, 2011, 186, 4164-4174.	0.8	9
1023	E. coli O104:H4 German outbreak: a missed opportunity. Nature Reviews Nephrology, 2012, 8, 558-560.	9.6	9
1024	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. Journal of Transplantation, 2012, 2012, 1-7.	0.5	9
1025	An Unanticipated Role for Survivin in Organ Transplant Damage. American Journal of Transplantation, 2014, 14, 1046-1060.	4.7	9
1026	A Multidrug, Antiproteinuric Approach to Alport Syndrome: A Ten-Year Cohort Study. Nephron, 2015, 130, 13-20.	1.8	9

#	ARTICLE	IF	CITATIONS
1027	A First Step toward a New Approach to Treating Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 86-88.	27.0	9
1028	Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine.. Journal of Lipid Research, 1989, 30, 1977-1981.	4.2	9
1029	Abnormal platelet function in haemodialysed patients: current concepts. International Journal of Artificial Organs, 1979, 2, 109-12.	1.4	9
1030	Nitric oxide/endothelin balance after nephron reduction. Kidney International, Supplement, 1998, 65, S63-7.	0.1	9
1031	Metabolism of arachidonic acid in isolated glomeruli from pig kidney. Lipids and Lipid Metabolism, 1988, 961, 110-121.	2.6	8
1032	Hyperparathyroidism Does Not Influence the Abnormal Primary Haemostasis in Patients with Chronic Renal Failure. Nephrology Dialysis Transplantation, 1989, 4, 971-974.	0.7	8
1033	Abnormalities of Arachidonate Metabolism in Experimental Ciclosporin Nephrotoxicity. American Journal of Nephrology, 1989, 9, 72-77.	3.1	8
1034	Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. Toxicology Letters, 1989, 46, 65-75.	0.8	8
1035	Morphometrical Analysis of Glomerular Changes Induced by Cyclosporine in the Rat. American Journal of Kidney Diseases, 1991, 17, 537-543.	1.9	8
1036	Idiopathic membranous nephropathy. Lancet, The, 1993, 342, 1277-1280.	13.7	8
1037	The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension. Current Opinion in Nephrology and Hypertension, 1996, 5, 347-352.	2.0	8
1038	Prognosis of diabetic nephropathy: how to improve the outcome. Diabetes Research and Clinical Practice, 1998, 39, S49-S53.	2.8	8
1039	Transplant tolerance: will genes protect the graft?. Lancet, The, 1998, 351, 1749-1751.	13.7	8
1040	IgA nephropathy: A stem cell disease?. Kidney International, 1999, 56, 1964-1966.	5.2	8
1041	Hyperhomocysteinemia and Increased Risk of Retinopathy: A cross-sectional, case-control study in patients with type 2 diabetes. Diabetes Care, 2002, 25, 2361-2361.	8.6	8
1042	Is Regression of Chronic Nephropathies a Therapeutic Target?. Journal of the American Society of Nephrology: JASN, 2005, 16, 840-842.	6.1	8
1043	Blood Cyclosporine Level Soon After Kidney Transplantation is a Major Determinant of Rejection: Insights From the Mycophenolate Steroid-Sparing Trial. Transplantation Proceedings, 2005, 37, 2037-2040.	0.6	8
1044	Idiopathic membranous nephropathy: back to the future?. Lancet, The, 2013, 381, 706-708.	13.7	8

#	ARTICLE	IF	CITATIONS
1045	Chronic kidney disease in sub-Saharan Africa: a public health priority. <i>The Lancet Global Health</i> , 2014, 2, e124-e125.	6.3	8
1046	Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis. <i>Nephron</i> , 2016, 133, 129-138.	1.8	8
1047	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3405-3412.	6.1	8
1048	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 130-137.	14.2	8
1049	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	3.1	8
1050	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. <i>Diabetes</i> , 2018, 67, 2069-2083.	0.6	8
1051	More about Factor H Autoantibodies in Membranous Nephropathy. <i>New England Journal of Medicine</i> , 2019, 381, 1590-1592.	27.0	8
1052	Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. <i>Kidney International</i> , 2020, 98, 1084-1087.	5.2	8
1053	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. <i>Frontiers in Medicine</i> , 2020, 7, 579418.	2.6	8
1054	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003668.	8.4	8
1055	Eicosanoids and Platelet Activating Factor as Possible Mediators of Injury in Experimental Nephropathies. <i>Advances in Experimental Medicine and Biology</i> , 1989, 259, 221-247.	1.6	8
1056	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. <i>Blood</i> , 1997, 90, 1558-1564.	1.4	8
1057	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home?. <i>Clinical and Medical Investigations</i> , 2020, 5, .	0.3	8
1058	Challenges in Understanding Acute Postinfectious Glomerulonephritis: Are Anti-Factor B Autoantibodies the Answer?. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 670-672.	6.1	8
1059	International Society of Nephrology's Perspective on the Emergence of Chronic Kidney Diseases of Unknown/Undetermined Etiology. <i>MEDICC Review</i> , 2014, 16, 75.	0.7	8
1060	Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine. <i>Journal of Lipid Research</i> , 1989, 30, 1977-81.	4.2	8
1061	Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. <i>Journal of Nephrology</i> , 2002, 15, 428-30.	2.0	8
1062	Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients.. <i>Journal of Clinical Pathology</i> , 1980, 33, 631-634.	2.0	7

#	ARTICLE	IF	CITATIONS
1063	Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats. American Journal of Physiology - Renal Physiology, 1991, 261, F85-F90.	2.7	7
1064	Treatment of idiopathic membranous glomerulopathy. Current Opinion in Nephrology and Hypertension, 1994, 3, 155-163.	2.0	7
1065	Recent developments in the management of membranous nephropathy. Expert Opinion on Investigational Drugs, 1997, 6, 521-532.	4.1	7
1066	Are HUS and TTP genetically determined?. Kidney International, 1998, 53, 1085-1086.	5.2	7
1067	Organs for Transplantation. New England Journal of Medicine, 2000, 343, 1730-1732.	27.0	7
1068	Renoprotection: Clues from knockout models of rare diseases. Kidney International, 2003, 63, 764-766.	5.2	7
1069	Autologous Stem Cell and Kidney Transplantation for Primary Amyloidosis Associated with ESRD: Which Should Come First?. American Journal of Transplantation, 2005, 5, 1585-1586.	4.7	7
1070	Misleading meta-analysis: a need to look beyond the headlines. Diabetic Medicine, 2007, 24, 587-591.	2.3	7
1071	Allograft Rejection: Acute and Chronic Studies. , 2008, 159, 122-134.		7
1072	Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitor-Free Regimen. Journal of Clinical Pharmacology, 2009, 49, 773-781.	2.0	7
1073	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports, 2009, 11, 118-124.	3.5	7
1074	Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy. American Journal of Transplantation, 2010, 10, 1336.	4.7	7
1075	Oral Acetyl- L -Carnitine Therapy and Insulin Resistance. Hypertension, 2010, 55, e26.	2.7	7
1076	Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome. , 2010, , 344-355.		7
1077	Hypertension after kidney transplantation. Journal of Hypertension, 2011, 29, 2310-2311.	0.5	7
1078	Epidemiology of End-Stage Renal Failure. , 2017, , 5-11.		7
1079	Invited letter in response to: "œls the kidney donor profile index (KDPI) universal or UNOS-specific?â€ American Journal of Transplantation, 2018, 18, 1033-1034.	4.7	7
1080	Mesenchymal Stromal Cells for AKI after Cardiac Surgery. Journal of the American Society of Nephrology: JASN, 2018, 29, 7-9.	6.1	7

#	ARTICLE	IF	CITATIONS
1081	Reply to the Comment by Dr. Cure on “Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade” Nephron, 2020, 144, 253-254.	1.8	7
1082	The impact of COVID-19 on total mortality in Italy up to November 2020. Panminerva Medica, 2021, , .	0.8	7
1083	Preventing microalbuminuria with benazepril, valsartan, and benazepril+valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. PLoS Medicine, 2021, 18, e1003691.	8.4	7
1084	IMMUNOMODULATION BY INTRATHYMIC INJECTION OF DONOR LEUKOCYTES IN RHESUS MONKEYS1. Transplantation, 2001, 72, 1432-1436.	1.0	7
1085	Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. Current Opinion in Nephrology and Hypertension, 2021, 30, 252-263.	2.0	7
1086	Need for chronic kidney disease prevention programs in disadvantaged populations. Clinical Nephrology, 2015, 83 (2015), 42-48.	0.7	7
1087	Thrombospondin induces glomerular mesangial cell adhesion and migration. Laboratory Investigation, 1992, 67, 566-71.	3.7	7
1088	Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: an inhibitor of protein C is present in uremic plasma. Thrombosis and Haemostasis, 1991, 66, 420-5.	3.4	7
1089	Endothelin in the progressive renal disease of glomerulopathies. Mineral and Electrolyte Metabolism, 1995, 21, 283-91.	1.1	7
1090	Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients. Haematologica, 2001, 86, 311-5.	3.5	7
1091	DOES ASPIRIN PRECIPITATE MAJOR GASTROINTESTINAL BLEEDING IN PATIENTS ON HÄMODIALYSIS?. Lancet, The, 1977, 310, 359-360.	13.7	6
1092	Platelet and vascular prostaglandins in uraemia, thrombotic microangiopathy and pre-eclampsia. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1981, 294, 339-342.	2.3	6
1093	Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. Lipids and Lipid Metabolism, 1989, 1006, 167-172.	2.6	6
1094	Identification of a Novel Gene “SSK1” in Human Endothelial Cells Exposed to Shear Stress. Biochemical and Biophysical Research Communications, 1998, 246, 881-887.	2.1	6
1095	Chronic Nephropathies: Individual Risk for Progression to End-Stage Renal Failure as Predicted by an Integrated Probabilistic Model. Nephron Clinical Practice, 2003, 95, c47-c59.	2.3	6
1096	Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene. PLoS Medicine, 2006, 3, e432.	8.4	6
1097	Does remission of renal disease associated with antihypertensive treatment exist?. Current Hypertension Reports, 2007, 9, 160-165.	3.5	6
1098	Î2-cell transplantation for diabetes therapy “Authors' reply. Lancet, The, 2008, 372, 29-30.	13.7	6

#	ARTICLE	IF	CITATIONS
1099	Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. <i>Kidney International</i> , 2008, 74, 1420-1428.	5.2	6
1100	Novel therapies of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 156-161.	2.0	6
1101	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017, 17, 441-448.	2.2	6
1102	Kidney Transplantation, Bioengineering, and Regeneration. , 2017, , xxv.		6
1103	Autotaxin Inhibitor Protects from Chronic Allograft Injury in Rat Kidney Allotransplantation. <i>Nephron</i> , 2020, 144, 38-48.	1.8	6
1104	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 575-587.	4.5	6
1105	Excess mortality in Italy in 2020 by sex and age groups accounting for demographic changes and temporal trends in mortality. <i>Panminerva Medica</i> , 2022, 64, .	0.8	6
1106	Non-Shiga toxin-associated hemolytic uremic syndrome. , 2006, , 65-83.		6
1107	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home? An update. <i>Clinical and Medical Investigations</i> , 2020, 5, .	0.3	6
1108	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. <i>EClinicalMedicine</i> , 2022, 43, 101240.	7.1	6
1109	FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. <i>Transplantation Proceedings</i> , 1991, 23, 3123-5.	0.6	6
1110	Renal handling of aspirin in the rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1989, 251, 295-304.	2.5	6
1111	Effect of platelet-activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney. <i>Laboratory Investigation</i> , 1988, 58, 163-71.	3.7	6
1112	Coagulation defects in uremia. <i>Kidney International, Supplement</i> , 1988, 24, S13-7.	0.1	6
1113	Prostacyclin and renal diseases. <i>Clinical Nephrology</i> , 1982, 18, 111-9.	0.7	6
1114	How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients?. <i>Clinical Transplantation</i> , 1998, 12, 379-90.	1.6	6
1115	The role of the endothelium in hemolytic uremic syndrome. <i>Journal of Nephrology</i> , 2001, 14 Suppl 4, S58-62.	2.0	6
1116	Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19. <i>Frontiers in Pharmacology</i> , 2022, 13, 842473.	3.5	6

#	ARTICLE	IF	CITATIONS
1117	Primary care in a National Health Service: time for radical reform. Family Practice, 2022, 39, 994-995.	1.9	6
1118	Excess total mortality in 2021 in Italy was about one third of that observed in 2020.. Medicina Del Lavoro, 2021, 112, 414-421.	0.4	6
1119	Pathogenesis of Preeclampsia. , 1986, , 13-33.		5
1120	Oral zeranol shortens the prolonged bleeding time of uremic rats. Kidney International, 1990, 38, 96-100.	5.2	5
1121	Low-dose aspirin and bleeding in uremia. American Journal of Hematology, 1993, 42, 235-236.	4.1	5
1122	Hemolytic uremic syndrome: Past and present. American Journal of Kidney Diseases, 2000, 36, liv-lvi.	1.9	5
1123	Tacrolimus and ciclosporin microemulsion in renal transplantation. Lancet, The, 2002, 360, 799-800.	13.7	5
1124	Can We Really Lessen Kidney Damage to the Point that the Loss of Renal Function of Progressive Nephropathy May Revert?. Journal of the American Society of Nephrology: JASN, 2003, 14, 1411-1414.	6.1	5
1125	Genetics of rare diseases of the kidney: learning from mouse models. Cytogenetic and Genome Research, 2004, 105, 479-484.	1.1	5
1126	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. Expert Opinion on Therapeutic Patents, 2004, 14, 1553-1566.	5.0	5
1127	Kidney prevention recipes for your office practice. Kidney International, 2005, 67, S136-S141.	5.2	5
1128	Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?. Journal of Hepatology, 2006, 44, 837-838.	3.7	5
1129	Complement hyperactivation may cause atypical haemolytic uraemic syndrome gain-of-function mutations in factor B. Nephrology Dialysis Transplantation, 2007, 22, 2452-2454.	0.7	5
1130	Candesartan and renal protection: more than blocking angiotensin type 1 receptor?. Kidney International, 2008, 74, 1112-1114.	5.2	5
1131	Islet transplantation: need for a time-out?. Nature Clinical Practice Nephrology, 2008, 4, 660-661.	2.0	5
1132	Effect of Seliciclib (CYC202, R-Roscovetine) on Lymphocyte Alloreactivity and Acute Kidney Allograft Rejection in Rat. Transplantation, 2008, 85, 1476-1482.	1.0	5
1133	Ethical disputes still beset Italian medicine 150 years after Count Cavour's death. Lancet, The, 2012, 379, 1068-1073.	13.7	5
1134	Recent advances in immunosuppression and acquired immune tolerance in renal transplants. American Journal of Physiology - Renal Physiology, 2016, 310, F446-F453.	2.7	5

#	ARTICLE	IF	CITATIONS
1135	Association of <i>CFHR1</i> homozygous deletion with acute myelogenous leukemia in the European population. <i>Leukemia and Lymphoma</i> , 2016, 57, 1234-1237.	1.3	5
1136	New biologics in the treatment of rare glomerular diseases of childhood. <i>Current Opinion in Pharmacology</i> , 2017, 33, 27-33.	3.5	5
1137	Acute Kidney Injury and Hemolytic Anemia Secondary to <i>Mycoplasma pneumoniae</i> Infection. <i>Nephron</i> , 2017, 137, 148-154.	1.8	5
1138	Should We Still Believe in Randomized Controlled Trials in Nephrology?. <i>Nephron</i> , 2017, 136, 281-286.	1.8	5
1139	Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. <i>Data in Brief</i> , 2018, 21, 2075-2081.	1.0	5
1140	Reply to "Strengths and limitations of estimated and measured GFR". <i>Nature Reviews Nephrology</i> , 2019, 15, 785-786.	9.6	5
1141	Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis. <i>Nephron</i> , 2021, 145, 428-444.	1.8	5
1142	Renal cyclophilin-like protein gene expression parallels changes in sodium excretion in experimental nephrosis and is positively modulated by atrial natriuretic peptide.. <i>Journal of the American Society of Nephrology: JASN</i> , 1993, 3, 1710-1716.	6.1	5
1143	Steroids and Adriamycin nephrosis. <i>Applied Pathology</i> , 1984, 2, 32-8.	0.3	5
1144	The possible role of endothelin in the process of progressive renal deterioration in experimental and human glomerulopathies. <i>Seminars in Nephrology</i> , 1993, 13, 137-43.	1.6	5
1145	Vascular access-related thrombotic complications: research hypotheses and therapeutic strategies. <i>Journal of Nephrology</i> , 2006, 19, 280-5.	2.0	5
1146	ASPHYXIA IN GOODPASTURE'S SYNDROME: EARLY TREATMENT BY IMMUNOSUPPRESSION AND PLASMA EXCHANGE. <i>Lancet, The</i> , 1978, 311, 552.	13.7	4
1147	STAGNATIONS AND REGRESSIONS IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS. <i>Lancet, The</i> , 1983, 322, 90-92.	13.7	4
1148	Renin-Angiotensin System and Glomerular Prostaglandins in Early Nephrotoxicity of Ciclosporin. <i>Contributions To Nephrology</i> , 1986, 51, 120-125.	1.1	4
1149	Steroids and Cytotoxic Drugs in the Treatment of Membranous Glomerulopathy. <i>Nephron</i> , 1988, 50, 263-264.	1.8	4
1150	Effects of Tertatolol on Renal Function in the Isolated Perfused Rat Kidney. <i>American Journal of Hypertension</i> , 1989, 2, 223S-227S.	2.0	4
1151	Induction of unresponsiveness via intrathymic inoculation. <i>Lancet, The</i> , 1991, 338, 450.	13.7	4
1152	Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. <i>Mediators of Inflammation</i> , 1992, 1, 263-266.	3.0	4

#	ARTICLE	IF	CITATIONS
1153	Inflammation and glomerular injury. Seminars in Immunopathology, 1994, 16, 39-51.	4.0	4
1154	The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. Prostaglandins Leukotrienes and Essential Fatty Acids, 1994, 51, 75-79.	2.2	4
1155	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs. Expert Opinion on Therapeutic Patents, 1996, 6, 871-891.	5.0	4
1156	Dearingâ€™a report to be embraced. Lancet, The, 1997, 350, 308.	13.7	4
1157	Assessment of glomerular size-selective function with fractional clearance of neutral dextran. Translational Research, 1998, 132, 360-362.	2.3	4
1158	Familial and Recurrent Forms of Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2001, 136, 125-139.		4
1159	Conflict of interest as seen from a researcherâ€™s perspective. Science and Engineering Ethics, 2002, 8, 337-342.	2.9	4
1160	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	4
1161	Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. Expert Opinion on Pharmacotherapy, 2005, 6, 1931-1942.	1.8	4
1162	KIDNEY FAILURE STABILIZES AFTER AN INCREASE OVER 2 DECADES. Journal of Renal Care, 2007, 33, 100-104.	1.2	4
1163	Lymphocyte depletion for kidney transplantation: back to the past?. Nature Clinical Practice Nephrology, 2008, 4, 534-535.	2.0	4
1164	Low Mortality and Key Aspects of Delivery of Care for End-Stage Renal Disease in Italy. Scientific World Journal, The, 2009, 9, 349-359.	2.1	4
1165	Meta-analyses can misdirect decisions on treatment. Nature Reviews Nephrology, 2013, 9, 311-312.	9.6	4
1166	Low-Dose RATG with or without Basiliximab in Renal Transplantation: A Matched-Cohort Observational Study. American Journal of Nephrology, 2015, 41, 16-27.	3.1	4
1167	Nephroprotection by dual RAS blockadeâ€™a welcome back. Nature Reviews Nephrology, 2015, 11, 507-508.	9.6	4
1168	Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. Nephron, 2017, 135, 173-180.	1.8	4
1169	Comparison of exposure response relationship of atrasentan between <scp>N</scp>orth <scp>A</scp>merican and <scp>A</scp>sian populations. Diabetes, Obesity and Metabolism, 2017, 19, 545-552.	4.4	4
1170	Recellularization of Kidney Scaffold With Stem Cells. , 2017, , 877-886.		4

#	ARTICLE	IF	CITATIONS
1171	CRISPR-Cas9-Mediated Correction of the G189R-PAX2 Mutation in Induced Pluripotent Stem Cells from a Patient with Focal Segmental Glomerulosclerosis. CRISPR Journal, 2019, 2, 108-120.	2.9	4
1172	Update on mesenchymal stromal cell studies in organ transplant recipients. Current Opinion in Organ Transplantation, 2020, 25, 27-34.	1.6	4
1173	Morphofunctional Effects of C5 Convertase Blockade in Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Report of Two Cases with Evidence of Terminal Complement Activation. Nephron, 2020, 144, 195-203.	1.8	4
1174	Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. Stem Cell Research, 2021, 55, 102476.	0.7	4
1175	Sirtuin 3 in acute kidney injury. Oncotarget, 2015, 6, 16814-16815.	1.8	4
1176	The kidney triggers graft-versus-host disease in experimental combined transplantation of kidney and stem cell-enriched peripheral leukocytes.. Journal of the American Society of Nephrology: JASN, 1996, 7, 2254-2258.	6.1	4
1177	Increased urinary excretion of endothelin-1 and its precursor, Big-endothelin-1, in rats chronically treated with cyclosporine. Transplantation, 1991, 52, 175-7.	1.0	4
1178	Pathogenesis and treatment of thrombotic microangiopathy. Kidney International, Supplement, 1997, 58, S97-101.	0.1	4
1179	Nitric oxide synthesis and L-arginine in uremia. Mineral and Electrolyte Metabolism, 1997, 23, 151-6.	1.1	4
1180	Angiotensin-converting enzyme inhibition prevents loss of glomerular hydraulic permeability in passive heyman nephritis. Laboratory Investigation, 1999, 79, 1501-10.	3.7	4
1181	Induction of unresponsiveness via intrathymic inoculation. Lancet, The, 1991, 337, 1487-1488.	13.7	3
1182	Interleukin-1 and Glomerular Mesangial Cells. Kidney and Blood Pressure Research, 1993, 16, 89-92.	2.0	3
1183	Interleukin-6 stimulates gene expression of extracellular matrix components in bovine mesangial cells in culture. Mediators of Inflammation, 1993, 2, 429-433.	3.0	3
1184	Innovative strategies for pharmacological intervention in immune damage to the kidney. Nephrology Dialysis Transplantation, 1995, 10, 1131-1136.	0.7	3
1185	The Girl with the Curl. New England Journal of Medicine, 1995, 333, 928-931.	27.0	3
1186	Renin-Angiotensin System, Proteinuria, and Tubulointerstitial Damage. , 2001, 135, 187-199.		3
1187	The scientific care for prevention: An overview. Kidney International, 2005, 67, S8-S13.	5.2	3
1188	Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2006, 28, 643-649.	2.0	3

#	ARTICLE	IF	CITATIONS
1189	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. <i>Kidney International</i> , 2007, 71, 1132-1141.	5.2	3
1190	Treatment of Chronic Proteinuric Kidney Disease. <i>Hypertension</i> , 2009, 54, 29-31.	2.7	3
1191	Omega-3 Polyunsaturated Fatty Acids Affect Sirolimus Exposure in Kidney Transplant Recipients on Calcineurin Inhibitor-Free Regimen. <i>Transplantation</i> , 2010, 89, 126-127.	1.0	3
1192	Comment on: Robertson (2010) Islet Transplantation a Decade Later and Strategies for Filling a Half-Full Glass. <i>Diabetes</i> ;59:1285-1291. <i>Diabetes</i> , 2010, 59, e13-e13.	0.6	3
1193	Dual RAS blockade“controversy resolved. <i>Nature Reviews Nephrology</i> , 2013, 9, 640-640.	9.6	3
1194	High serum cholesterol: a missed risk factor for chronic kidney disease mortality. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 613-614.	11.4	3
1195	Albuminuria Regression in Diabetes: A Therapeutic Target for Nephro- and Cardio-Protection, in <i>Clinics and Research. American Journal of Nephrology</i> , 2019, 49, 143-145.	3.1	3
1196	Preimplantation Histological Score Associates with 6-Month GFR in Recipients of Perfused, Older Kidney Grafts: Results from a Pilot Study. <i>Nephron</i> , 2021, 145, 137-149.	1.8	3
1197	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. <i>Stem Cell Research and Therapy</i> , 2021, 12, 332.	5.5	3
1198	ADP, Ristocetin, Bovine Factor VIII and Thrombasthenic Platelets. <i>Thrombosis and Haemostasis</i> , 1976, 36, 286-288.	3.4	3
1199	Genes and molecular medicine in the future of organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 1999, 4, 65.	1.6	3
1200	Imaging the Kidney with an Unconventional Scanning Electron Microscopy Technique: Analysis of the Subpodocyte Space in Diabetic Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1699.	4.1	3
1201	Tertatolol ameliorates renal function in rats with chronic renal failure. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1988, 246, 287-93.	2.5	3
1202	The hemolytic uremic syndrome. <i>International Journal of Artificial Organs</i> , 1985, 8, 171-4.	1.4	3
1203	Heparin for hemodialysis: practical guidelines for administration and monitoring. <i>International Journal of Artificial Organs</i> , 1984, 7, 269-74.	1.4	3
1204	Studies of privileged sites and organ transplantation. <i>Experimental Nephrology</i> , 1993, 1, 120-7.	0.4	3
1205	How much must blood pressure be reduced in order to obtain the remission of chronic renal disease?. <i>Journal of Nephrology</i> , 2000, 13, 228-31.	2.0	3
1206	Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome. <i>Cells</i> , 2022, 11, 1755.	4.1	3

#	ARTICLE	IF	CITATIONS
1207	Vascular Prostacyclin and Plasminogen Activator Activity in Experimental and Clinical Conditions of Disturbed Haemostasis or Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1979, 8, 300-311.	0.3	2
1208	Platelets from Uraemic Patients React Normally to Prostacyclin. International Journal of Artificial Organs, 1980, 3, 125-125.	1.4	2
1209	Transplant tolerance: facts and future. Transplantation Proceedings, 1999, 31, 2955-2957.	0.6	2
1210	Prostacyclin and Thromboxane and the Development of Preeclampsia. JAMA - Journal of the American Medical Association, 2000, 283, 1568.	7.4	2
1211	Thrombotic Microangiopathies in the Intensive Care Unit: Many Questions, Some Answers. , 2001, 132, 53-67.		2
1212	Nitric oxide and renal perfusion in humans. Journal of Hypertension, 2002, 20, 391-393.	0.5	2
1213	Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?. Current Hypertension Reports, 2003, 5, 364-367.	3.5	2
1214	Antihypertensive therapy in chronic renal disease. Journal of Hypertension, 2003, 21, 1625-1626.	0.5	2
1215	Effect of a Novel Immunosuppressant, ST1959, on the Immune System and Renal Allograft Survival in Rats. Transplantation, 2005, 80, 231-236.	1.0	2
1216	What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?. Nature Clinical Practice Nephrology, 2006, 2, 250-251.	2.0	2
1217	Introduction to Focus on Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 359.	4.5	2
1218	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. Journal of Hypertension, 2011, 29, 2031-2037.	0.5	2
1219	Optimizing Allocation of Kidneys from Older Donors. American Journal of Transplantation, 2011, 11, 182-182.	4.7	2
1220	LITERATURE WatchImplications for transplantation. American Journal of Transplantation, 2013, 13, 1625-1625.	4.7	2
1221	ISN-ACCTS: global initiatives to improve clinical research. Nature Reviews Nephrology, 2014, 10, 426-427.	9.6	2
1222	Stamina therapies: Time to call a halt. Nature, 2014, 506, 434-434.	27.8	2
1223	The Lancet Kidney Campaign: an opportunity for partnerships. Lancet, The, 2016, 387, 1038-1039.	13.7	2
1224	Italy, the Land of Holy Miracles"revisited. Lancet, The, 2016, 387, 11-12.	13.7	2

#	ARTICLE	IF	CITATIONS
1225	SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. Nephrology Dialysis Transplantation, 2018, 33, i317-i317.	0.7	2
1226	A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. BMC Medical Research Methodology, 2018, 18, 110.	3.1	2
1227	The Glomerulus: Mechanisms and Patterns of Injury. , 2018, , 189-206.		2
1228	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. Nephron, 2019, 142, 264-270.	1.8	2
1229	Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney Medicine, 2020, 2, 804-809.	2.0	2
1230	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. Frontiers in Immunology, 2021, 12, 711915.	4.8	2
1231	Insights into Glomerular Filtration and Albuminuria. New England Journal of Medicine, 2021, 385, 477-478.	27.0	2
1232	Cyclosporine/tacrolimus (FK-506). , 1998, , 275-300.		2
1233	Thrombotic Microangiopathies. , 2008, , 294-312.		2
1234	Why rare diseases?. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 94-7.	0.4	2
1235	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. Acta Diabetologica, 2022, 59, 309-317.	2.5	2
1236	The Glomerulus: Mechanisms and Patterns of Injury. , 2014, , .		2
1237	Proteinuria and Tubulotoxicity. , 2019, , 197-214.		2
1238	Unravelling the Role of PAX2 Mutation in Human Focal Segmental Glomerulosclerosis. Biomedicines, 2021, 9, 1808.	3.2	2
1239	Abdominal pain and acute nephritis in a man with a recent renal transplant. Journal of Nephrology, 1998, 11, 196-8.	2.0	2
1240	Mechanisms of progression of chronic renal disease. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2002, 13, 250-6.	0.3	2
1241	Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. Journal of Immunology, 2022, 208, 1772-1781.	0.8	2
1242	Aspirin and Thrombosis in Patients Undergoing Hemodialysis. New England Journal of Medicine, 1980, 302, 1420-1421.	27.0	1

#	ARTICLE	IF	CITATIONS
1243	Are "Routine" Clinical and Laboratory Examinations of Any Help in the Treatment of Chronic Hemodialysis Patients?. American Journal of Kidney Diseases, 1987, 10, 23-27.	1.9	1
1244	Prostacyclin and Hemolytic Uremic Syndrome: From the Laboratory to An International Registry. International Journal of Artificial Organs, 1987, 10, 337-340.	1.4	1
1245	Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. Biochemical Medicine and Metabolic Biology, 1992, 48, 219-226.	0.7	1
1246	Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. Kidney International, 1993, 44, 747-754.	5.2	1
1247	Reduced Fibrinolytic Activity in Glomeruli Isolated from Rabbits Infused with Tumor Necrosis Factor. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 173-178.	0.3	1
1248	Reducing mortality and increasing awareness. Lancet, The, 1998, 352, S20.	13.7	1
1249	Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. Transplantation Proceedings, 1998, 30, 1654-1655.	0.6	1
1250	Optimization of cyclosporine therapy in kidney transplantation. Transplantation Proceedings, 1998, 30, 1673-1676.	0.6	1
1251	Gene Therapy to the Kidney. , 2001, 136, 140-156.		1
1252	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. Personalized Medicine, 2004, 1, 53-62.	1.5	1
1253	How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease?. Nature Clinical Practice Nephrology, 2007, 3, 126-127.	2.0	1
1254	More on Renal Disease Progression: Is Interstitial Inflammation Truly Protective?. Journal of the American Society of Nephrology: JASN, 2007, 18, 1630-1632.	6.1	1
1255	Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study. Clinical Therapeutics, 2007, 29, S64-S72.	2.5	1
1256	Role of Proteinuria in Progression. , 2008, , 2563-2576.		1
1257	New strategies to prevent cardiovascular risk in chronic kidney disease. Kidney International, 2008, 74, S1.	5.2	1
1258	Pathophysiology of Chronic Kidney Disease. , 2009, , 422-435.		1
1259	Medicine and art: one culture?. Kidney International, 2009, 75, 347-348.	5.2	1
1260	ERA-EDTA Immunonephrology working group. Nephrology Dialysis Transplantation, 2010, 25, 1706-1707.	0.7	1

#	ARTICLE	IF	CITATIONS
1261	Exciting times for renal medicine. Lancet, The, 2010, 375, 1227-1228.	13.7	1
1262	Bone Marrow Mesenchymal Stem Cells in Organ Repair and Strategies to Optimize their Efficacy. , 2011, , 299-312.		1
1263	Initial combination therapy for treatment of hypertension. Lancet, The, 2011, 377, 1491.	13.7	1
1264	In patients with atypical hemolytic uremic syndrome C5 activation causes loss of endothelial thromboresistance. Molecular Immunology, 2011, 48, 1680.	2.2	1
1265	Thrombotic microangiopathies. , 2012, , 278-282.		1
1266	Role of Proteinuria in the Progression of Renal Disease. , 2013, , 2961-2983.		1
1267	Kidney Transplantation From a Donor With Acute Kidney Injury: An Unexpected Outcome. American Journal of Transplantation, 2014, 14, 977-978.	4.7	1
1268	Dreaming of normoglycaemia with fewer diet restrictions. Lancet Diabetes and Endocrinology,the, 2014, 2, 350-351.	11.4	1
1269	West Meets East. Kidney Diseases (Basel, Switzerland), 2015, 1, 4-7.	2.5	1
1270	Interplay between Diagnostic Criteria and Prognostic Accuracy in Chronic Kidney Disease. PLoS Medicine, 2016, 13, e1002129.	8.4	1
1271	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€”The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.8	1
1272	Mesenchymal stromal cell-based therapy in kidney diseases and transplantation. Italian Journal of Medicine, 2019, 13, 3-14.	0.3	1
1273	Bleeding and Hemostasis in Acute Renal Failure. , 2019, , 630-635.e2.		1
1274	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. Cell Transplantation, 2020, 29, 096368972096546.	2.5	1
1275	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation. SSRN Electronic Journal, 0, , .	0.4	1
1276	Prevention of Chronic Renal Diseases in the Elderly. , 2008, , 231-255.		1
1277	Thrombotic Microangiopathy. , 1998, , 513-527.		1
1278	The Onset and Resolution of Renal Fibrosis. , 2016, , 351-366.		1

#	ARTICLE	IF	CITATIONS
1279	Treatment of Anemia and Bleeding in Chronic Kidney Disease. , 2008, , 756-764.		1
1280	Nephropathy in NIDDM Patients, Predictors of Outcome. , 2000, , 237-246.		1
1281	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	1
1282	Kidney Disease. , 2017, , 235-252.		1
1283	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	1
1284	Severe glomerular epithelial cell damage does not prevent passive Heyman nephritis in rats. Clinical and Experimental Immunology, 1983, 51, 38-44.	2.6	1
1285	Possible role of HLA-B8 antigen as a genetic marker of autoimmune thrombocytopenia in a patient with myasthenia gravis. Thrombosis and Haemostasis, 1977, 38, 593-4.	3.4	1
1286	Innovative strategies for pharmacological intervention in immune damage to the kidney. Nephrology Dialysis Transplantation, 1995, 10, 1131-6.	0.7	1
1287	Immunotolerance: from new knowledge of mechanisms of self-tolerance to future perspectives for induction of renal transplant tolerance. Experimental Nephrology, 1995, 3, 319-30.	0.4	1
1288	Xenotransplantation: a challenge for the future of transplant medicine. Swiss Medical Weekly, 1998, 128, 952-60.	1.6	1
1289	Treatment of adult hemolytic-uremic syndrome. Advances in Nephrology From the Necker Hospital, 2000, 30, 83-94.	0.2	1
1290	Halting the progression of renal disease: where we stand?. Nefrologia, 2002, 22, 303-5.	0.4	1
1291	Haemolytic Uraemic Syndromes. , 1984, , 276-297.		0
1292	Effect of Ticlopidine on the Evolution of Renal Disease in Rats with Reduced Renal Mass. Contributions To Nephrology, 1990, 81, 279-288.	1.1	0
1293	Renal pathophysiology. Current Opinion in Nephrology and Hypertension, 1993, 2, 597-601.	2.0	0
1294	Haemolyticâ€”Uraemic Syndrome and Thrombotic Thrombocytopenic Purpura. Vascular Medicine Review, 1993, vmr-4, 273-292.	0.3	0
1295	Kidney/pancreas transplantation. Lancet, The, 1994, 343, 971-972.	13.7	0
1296	Renal pathophysiology. Current Opinion in Nephrology and Hypertension, 1994, 3, 431-435.	2.0	0

#	ARTICLE	IF	CITATIONS
1297	Hemostasis in renal failure. <i>Intensivmedizin Und Notfallmedizin</i> , 1998, 35, 382-389.	0.2	0
1298	Double transplant of marginal kidneys. <i>Transplantation Proceedings</i> , 1999, 31, 2962-2964.	0.6	0
1299	The uses of error: diagnostic preferences. <i>Lancet, The</i> , 2001, 358, 1005.	13.7	0
1300	Corrigendum to "Letâ€™s assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?" [Hepatol 44 (2006) 837â€“838]. <i>Journal of Hepatology</i> , 2006, 45, 339.	3.7	0
1301	Angiotensin-receptor blockers for renal protection in Type 2 diabetes. <i>Aging Health</i> , 2006, 2, 295-301.	0.3	0
1302	Is Mycophenolate Mofetil Better Than Azathioprine in Organ Transplantation?. <i>Transplantation</i> , 2006, 82, 1242-1243.	1.0	0
1303	A mouse model of non-Shiga toxin-associated haemolytic uraemic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 462-465.	0.7	0
1304	Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. <i>Handbook of Systemic Autoimmune Diseases</i> , 2007, , 257-282.	0.1	0
1305	Target haemoglobin concentrations in chronic kidney disease. <i>Lancet, The</i> , 2007, 369, 1515.	13.7	0
1306	Minimisation of immunosuppression in transplantation â€“ Authors' reply. <i>Lancet, The</i> , 2007, 370, 654.	13.7	0
1307	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2008, , 445-456.		0
1308	Rare but Relevant Kidney Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1701-1704.	4.5	0
1309	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial. <i>Diabetes Care</i> , 2010, 33, e133-e133.	8.6	0
1310	The Glomerulus: Mechanisms of Injury*. , 2010, , 245-261.		0
1311	Staging CKD: can we rely on estimated GFRs?. <i>Nature Reviews Nephrology</i> , 2011, 7, 307-308.	9.6	0
1312	Cells for Treating Organ Damage: How Long Will We Need Them?. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 590-592.	6.1	0
1313	Cavour's death and the political difficulties of Italian medicine â€“ Author's reply. <i>Lancet, The</i> , 2012, 380, 108-109.	13.7	0
1314	Prednisolone plus chlorambucil preserved renal function in membranous nephropathy. <i>Annals of Internal Medicine</i> , 2013, 158, JC9.	3.9	0

#	ARTICLE	IF	CITATIONS
1315	Current Status of Islet Transplantation. , 2014, , 583-598.		0
1316	Nephrons are generated via a series of committed progenitors. Nature Reviews Nephrology, 2014, 10, 491-491.	9.6	0
1317	Pharmacotherapy options for membranous nephropathy. Expert Opinion on Orphan Drugs, 2016, 4, 185-196.	0.8	0
1318	AAV9-mediated engineering of autotransplanted kidney of non-human primates. Gene Therapy, 2017, 24, 308-313.	4.5	0
1319	The Vaticanâ€“Mario Negriâ€“ Lancet Commission on the value of life. Lancet, The, 2017, 390, 1573.	13.7	0
1320	Addressing acute kidney injury in critically ill newborn babies. The Lancet Child and Adolescent Health, 2017, 1, 161-163.	5.6	0
1321	Developmental Approaches to Kidney Regeneration. , 2017, , 1039-1050.		0
1322	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2017, , 334-345.e1.		0
1323	Maintenance Immunosuppression in Kidney Transplantation. , 2017, , 259-276.		0
1324	Hemolytic Uremic Syndrome. , 2019, , 294-301.e2.		0
1325	Orphan drugs â€“ Authors' reply. Lancet, The, 2019, 393, 1595-1596.	13.7	0
1326	Why and how did Leonardo happen: the Renaissance context. Lancet, The, 2019, 393, 1396-1397.	13.7	0
1327	<i>Nephrology Worldwide</i> â€“ A Book Review. Nephron, 2021, 145, 212-213.	1.8	0
1328	COVID-19 from a pharmacological perspective. Advances in Biological Regulation, 2021, 81, 100821.	2.3	0
1329	Molecular Medicine in Organ Transplantation: How and When?. , 2001, , 317-334.		0
1330	Pharmacologic Monitoring of Immunosuppressive Drugs. , 2001, , 43-59.		0
1331	Platelets and renal diseases. , 2002, , 837-851.		0
1332	Mesenchymal Stem Cells and Their Use in Acute Renal Injury. , 2009, , 216-220.		0

#	ARTICLE	IF	CITATIONS
1333	Bleeding and Hemostasis in Acute Renal Failure. , 2009, , 385-390.		0
1334	Hemolytic Uremic Syndrome. , 2009, , 373-378.		0
1335	Acute Renal Failure in Kidney Transplant Recipients. , 2009, , 1660-1665.		0
1336	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2010, , 349-364.		0
1337	Nondiabetic Kidney Disease. , 2010, , 341-356.		0
1338	Platelet and Vascular Prostaglandins in Uraemia, Thrombotic Microangiopathy and Pre-Eclampsia. , 1982,, 209-215.		0
1339	Prostanoid-Related Platelet Abnormalities in Renal Disease. , 1984, , 1406-1411.		0
1340	Eicosanoids and Acute Renal Failure. Current Concepts in Critical Care, 1990, , 115-129.	0.1	0
1341	Models of human renal disease. , 1990, , 111-123.		0
1342	Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes. , 1991, , 543-554.		0
1343	Altered Renovascular Endothelial Functions During Nephrotoxicity. , 1991, , 157-166.		0
1344	Aspirin in Hypertension of Pregnancy. , 1992, , 93-105.		0
1345	A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome. , 1997, , 418-427.		0
1346	Successes and Disappointments with Clinical Islet Transplantation. , 2015, , 1245-1274.		0
1347	Reply: Nephrons are generated via a series of committed progenitors. Nature Reviews Nephrology, 0, , .	9.6	0
1348	Commenti alla delibera. Mecosan, 2017, , 173-180.	0.1	0
1349	Acute Renal Failure in Kidney Transplant Recipients. , 2019, , 1279-1285.e3.		0
1350	Platelet and Vascular Prostaglandins in Uremia and Thrombotic Microangiopathy. , 1983, , 319-325.		0

#	ARTICLE	IF	CITATIONS
1351	Thrombogenesis and Anticoagulation in Patients Undergoing Chronic Hemodialysis. , 1996, , 323-332.		0
1352	Interstitial Nephritis. , 2006, , 636-642.		0
1353	ADP, ristocetin, bovine factor VII and thrombasthenic platelets. Thrombosis and Haemostasis, 1976, 36, 286-8.	3.4	0
1354	Prostacyclin and hemolytic uremic syndrome: from the laboratory to an international registry. International Journal of Artificial Organs, 1987, 10, 337-40.	1.4	0
1355	Platelets from uraemic patients react normally to prostacyclin. International Journal of Artificial Organs, 1980, 3, 125.	1.4	0
1356	Glomerulonephritis: from new knowledge on the mechanisms of tissue damage to novel therapies. Current Opinion in Nephrology and Hypertension, 1995, 4, 374-82.	2.0	0
1357	Renal transplant tolerance: molecular mechanisms of T cell regulation. Introduction. Experimental Nephrology, 1993, 1, 69-71.	0.4	0
1358	Intrathymic transplantation of donor cells allows a stabilized, incompatible renal transplant to survive indefinitely after cyclosporine withdrawal. Experimental Nephrology, 1993, 1, 185-9.	0.4	0
1359	Endothelin and renal disease progression. Experimental Nephrology, 1994, 2, 133.	0.4	0
1360	Molecular basis of familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2003, 14, 342-50.	0.3	0
1361	Lupus Nephritis. , 0, , 244-252.		0
1362	Prostacyclin and Thromboxane and the Development of Preeclampsia. JAMA - Journal of the American Medical Association, 2000, 283, 1568-1569.	7.4	0